<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>67 Interleukins, Growth Factors And Targeted Therapies - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">30</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x573d1a=_0x2a41;(function(_0x399b4e,_0x1adb6a){const _0x2bd313=_0x2a41,_0x2392d2=_0x399b4e();while(!![]){try{const _0x206d96=-parseInt(_0x2bd313(0x20f))/0x1+parseInt(_0x2bd313(0x3fe))/0x2*(parseInt(_0x2bd313(0x2be))/0x3)+parseInt(_0x2bd313(0x2b2))/0x4*(parseInt(_0x2bd313(0x214))/0x5)+-parseInt(_0x2bd313(0x1e2))/0x6+parseInt(_0x2bd313(0x3a5))/0x7*(-parseInt(_0x2bd313(0x37d))/0x8)+parseInt(_0x2bd313(0x31d))/0x9*(parseInt(_0x2bd313(0x47b))/0xa)+parseInt(_0x2bd313(0x4b6))/0xb;if(_0x206d96===_0x1adb6a)break;else _0x2392d2['push'](_0x2392d2['shift']());}catch(_0x4b09c8){_0x2392d2['push'](_0x2392d2['shift']());}}}(_0x50fb,0xab753));const _0x522cc3=(function(){const _0x5ab984=_0x2a41,_0x8dc014={'VUGiM':function(_0x50b5fd,_0x548d64,_0x408fad){return _0x50b5fd(_0x548d64,_0x408fad);},'ojKge':function(_0x45107d,_0xd4c0c4){return _0x45107d!==_0xd4c0c4;},'HGkHh':_0x5ab984(0x4a4),'zGVba':'testModeReviewLegend','mJvLX':'test','CjGJI':_0x5ab984(0x367),'EcRrt':_0x5ab984(0x2bc),'fMCRu':_0x5ab984(0x356),'helGG':_0x5ab984(0x49b),'xbLCg':_0x5ab984(0x2ff),'NRavC':_0x5ab984(0x22f),'ZdUHj':_0x5ab984(0x3f1),'SHCOa':function(_0x3da9a4,_0x4fcf1f){return _0x3da9a4<_0x4fcf1f;},'rcYYv':function(_0x9c9962,_0xdb2080){return _0x9c9962===_0xdb2080;},'MNETz':'iyEnn','OTETd':_0x5ab984(0x364)};let _0x58e819=!![];return function(_0x557dcf,_0x240050){const _0x4fa7bd=_0x5ab984,_0x59a84f={'nEmGQ':'bookmarkBtn','ynZoO':_0x8dc014[_0x4fa7bd(0x474)],'ZWJCo':function(_0x1a9554,_0x1d9c22){return _0x1a9554===_0x1d9c22;},'WtSFY':_0x8dc014[_0x4fa7bd(0x26e)],'EPbGK':_0x8dc014[_0x4fa7bd(0x4a7)],'OKXaL':_0x8dc014['EcRrt'],'UeGJU':_0x8dc014[_0x4fa7bd(0x44e)],'eiVmn':_0x8dc014[_0x4fa7bd(0x307)],'yghOn':_0x8dc014[_0x4fa7bd(0x4cc)],'tNMcr':_0x8dc014[_0x4fa7bd(0x407)],'Njgqr':_0x8dc014[_0x4fa7bd(0x2c4)],'JOFTx':_0x4fa7bd(0x4a3),'rlOto':_0x4fa7bd(0x239),'TuMGq':function(_0x3afe1d,_0x4aba80){const _0x1e8cf4=_0x4fa7bd;return _0x8dc014[_0x1e8cf4(0x280)](_0x3afe1d,_0x4aba80);},'ypssi':function(_0x50adc3){return _0x50adc3();}};if(_0x8dc014[_0x4fa7bd(0x3a0)](_0x8dc014['MNETz'],_0x8dc014['OTETd']))_0x8dc014[_0x4fa7bd(0x439)](_0xedd110,_0x1d0055,_0x70e5d);else{const _0x4a626c=_0x58e819?function(){const _0x26386f=_0x4fa7bd;if(_0x8dc014[_0x26386f(0x25e)](_0x8dc014[_0x26386f(0x237)],_0x26386f(0x301))){if(_0x240050){const _0x19730c=_0x240050[_0x26386f(0x4b0)](_0x557dcf,arguments);return _0x240050=null,_0x19730c;}}else{_0x3bcbcf=_0x3a66d1[_0x26386f(0x30f)]();const _0x1c3ccf=_0x475f1c[_0x26386f(0x3d2)](_0x59a84f[_0x26386f(0x36d)]),_0x459bb8=_0x59facd[_0x26386f(0x3d2)]('markReviewBtn'),_0x4028c0=_0x4d3525['getElementById'](_0x59a84f[_0x26386f(0x240)]),_0x46dc51=_0x59a84f['ZWJCo'](_0x33a6e8,_0x59a84f[_0x26386f(0x20a)])||_0x59a84f[_0x26386f(0x1d0)](_0x42c599,_0x59a84f['EPbGK']);_0x4cec7a[_0x26386f(0x3d2)](_0x59a84f[_0x26386f(0x385)])[_0x26386f(0x46c)]['display']=_0x46dc51?_0x26386f(0x2ff):_0x59a84f['UeGJU'],_0xc79bb7['getElementById'](_0x59a84f['eiVmn'])[_0x26386f(0x46c)][_0x26386f(0x2b4)]=_0x46dc51?_0x59a84f[_0x26386f(0x343)]:_0x59a84f[_0x26386f(0x31c)],_0x19ba55[_0x26386f(0x3d2)](_0x59a84f[_0x26386f(0x1fd)])[_0x26386f(0x46c)][_0x26386f(0x2b4)]=_0x46dc51?_0x26386f(0x356):_0x59a84f['yghOn'],_0x3538c9[_0x26386f(0x3d2)](_0x26386f(0x411))[_0x26386f(0x46c)][_0x26386f(0x2b4)]=_0x46dc51?'block':_0x59a84f[_0x26386f(0x343)],_0x1c3ccf['style'][_0x26386f(0x2b4)]=_0x46dc51?_0x59a84f[_0x26386f(0x343)]:_0x59a84f[_0x26386f(0x274)],_0x459bb8[_0x26386f(0x46c)][_0x26386f(0x2b4)]=_0x46dc51?_0x59a84f['Njgqr']:_0x59a84f['yghOn'],_0x4028c0[_0x26386f(0x46c)]['display']=_0x46dc51?_0x59a84f['Njgqr']:_0x59a84f[_0x26386f(0x343)],(_0x59a84f[_0x26386f(0x1d0)](_0x1c4bd7,_0x59a84f[_0x26386f(0x4c5)])||_0x3171c4===_0x26386f(0x367))&&_0x173327[_0x26386f(0x3d2)](_0x59a84f[_0x26386f(0x462)])['classList'][_0x26386f(0x2cf)]('hidden'),!_0x159794(_0x4ee734)&&_0x202ff7>=0x0&&_0x59a84f['TuMGq'](_0x46f93c,_0x1365db['length'])&&(_0x3ca834=_0x5b2b63),_0x59a84f[_0x26386f(0x2f3)](_0x138ac8),_0x537c57(),_0x59a84f[_0x26386f(0x2f3)](_0x560b27),_0x59a84f[_0x26386f(0x2f3)](_0x2881fa);}}:function(){};return _0x58e819=![],_0x4a626c;}};}()),_0xdc9229=_0x522cc3(this,function(){const _0x5dd7ad=_0x2a41,_0x3e35c0={'cvvEa':'(((.+)+)+)+$'};return _0xdc9229[_0x5dd7ad(0x2fd)]()[_0x5dd7ad(0x3d4)](_0x3e35c0[_0x5dd7ad(0x48c)])['toString']()[_0x5dd7ad(0x4b5)](_0xdc9229)['search'](_0x3e35c0[_0x5dd7ad(0x48c)]);});_0xdc9229();const _0x38019d=(function(){const _0x4a9b25=_0x2a41,_0x5dfe13={'YMlwK':'jraym','fjuAg':_0x4a9b25(0x4bd),'MfAgB':function(_0x4a0f0,_0x379de8){return _0x4a0f0+_0x379de8;},'wwgyj':_0x4a9b25(0x4d1),'gBvNQ':_0x4a9b25(0x340),'UPlJa':function(_0x2a6b2e){return _0x2a6b2e();},'fvemo':function(_0x3480df,_0x5a5851){return _0x3480df===_0x5a5851;},'vpIFx':_0x4a9b25(0x28a)};let _0x32fb8b=!![];return function(_0x298660,_0x449beb){const _0x2ba60c=_0x4a9b25,_0x359900={'fMNOn':function(_0x7b3764){const _0x48f3b6=_0x2a41;return _0x5dfe13[_0x48f3b6(0x45a)](_0x7b3764);}};if(_0x5dfe13[_0x2ba60c(0x2a2)]('XlKEh',_0x5dfe13['vpIFx'])){const _0x4615cf=_0x32fb8b?function(){const _0x31a04e=_0x2ba60c;if(_0x449beb){if(_0x5dfe13[_0x31a04e(0x44d)]!=='jraym')_0x4e7d19[_0x31a04e(0x2a7)](),_0x359900[_0x31a04e(0x4c9)](_0xc13f44);else{const _0x103911=_0x449beb[_0x31a04e(0x4b0)](_0x298660,arguments);return _0x449beb=null,_0x103911;}}}:function(){};return _0x32fb8b=![],_0x4615cf;}else{const _0x9f3b1d=_0x5dfe13[_0x2ba60c(0x26c)][_0x2ba60c(0x4a2)]('|');let _0x385129=0x0;while(!![]){switch(_0x9f3b1d[_0x385129++]){case'0':_0xdd936b=_0x31bdbd[_0x2ba60c(0x4c8)];continue;case'1':_0x10e267['getElementById'](_0x2ba60c(0x33f))[_0x2ba60c(0x235)]=_0x3c5901['length'];continue;case'2':_0x395cb1[_0x2ba60c(0x244)]=_0x5dfe13[_0x2ba60c(0x464)](_0x9d0512,_0x5dfe13[_0x2ba60c(0x29b)]);continue;case'3':_0x1a1d55=_0x328fb1[_0x2ba60c(0x2bd)];continue;case'4':_0x577b33[_0x2ba60c(0x3d2)](_0x5dfe13['gBvNQ'])[_0x2ba60c(0x235)]=_0x5144fc['join'](_0x2ba60c(0x35c));continue;case'5':_0x574ce6=_0x2a5181[_0x2ba60c(0x1dc)];continue;}break;}}};}()),_0x2fb938=_0x38019d(this,function(){const _0x5ddfab=_0x2a41,_0x3b7154={'tgayn':function(_0xde0e94){return _0xde0e94();},'TRbgr':function(_0x4946ac){return _0x4946ac();},'MVXvu':function(_0x1ab50b,_0x267fd1){return _0x1ab50b!==_0x267fd1;},'kNPHL':_0x5ddfab(0x35a),'IfJHG':_0x5ddfab(0x401),'TQFbX':function(_0xd543d0,_0x22423e){return _0xd543d0(_0x22423e);},'eCzYG':function(_0x327564,_0x55af27){return _0x327564+_0x55af27;},'nAllp':'return\x20(function()\x20','QQDfq':_0x5ddfab(0x278),'JXUJj':_0x5ddfab(0x2f0),'BOqpl':'markReviewText','mYDtz':_0x5ddfab(0x31a),'MYUdx':_0x5ddfab(0x430),'NVYfp':'Marked','XzLhl':'Mark\x20for\x20Review','vsxeb':_0x5ddfab(0x3d3),'CmqfZ':_0x5ddfab(0x3d5),'tGfmS':'error','KLzmO':'exception','wUOoD':'table','MhqDS':_0x5ddfab(0x3f8),'LyQMN':function(_0x3ca8b8,_0x177fbf){return _0x3ca8b8<_0x177fbf;},'loeAh':_0x5ddfab(0x2f4)},_0x2ef89a=function(){const _0x194cfe=_0x5ddfab;if(_0x3b7154['MVXvu'](_0x3b7154[_0x194cfe(0x421)],_0x3b7154[_0x194cfe(0x421)])){const _0xf88aa=_0x53dd80[_0x194cfe(0x4b5)]['prototype'][_0x194cfe(0x23a)](_0x42f7e9),_0x1b5901=_0xbe99a5[_0x4d005f],_0x12549c=_0x1a8cb3[_0x1b5901]||_0xf88aa;_0xf88aa[_0x194cfe(0x2e9)]=_0x4bcd02[_0x194cfe(0x23a)](_0x45e08d),_0xf88aa[_0x194cfe(0x2fd)]=_0x12549c[_0x194cfe(0x2fd)][_0x194cfe(0x23a)](_0x12549c),_0x3b0c31[_0x1b5901]=_0xf88aa;}else{let _0x513752;try{_0x3b7154[_0x194cfe(0x3a9)](_0x3b7154[_0x194cfe(0x481)],_0x3b7154[_0x194cfe(0x481)])?(_0x380cf6++,_0x3b7154[_0x194cfe(0x449)](_0x3e144b),_0x3b7154[_0x194cfe(0x46b)](_0x48cafc)):_0x513752=_0x3b7154[_0x194cfe(0x32f)](Function,_0x3b7154[_0x194cfe(0x424)](_0x3b7154[_0x194cfe(0x20c)]+_0x3b7154[_0x194cfe(0x459)],');'))();}catch(_0x12af3a){_0x513752=window;}return _0x513752;}},_0x38dc1f=_0x2ef89a(),_0x478371=_0x38dc1f['console']=_0x38dc1f[_0x5ddfab(0x286)]||{},_0x60e9cf=[_0x3b7154[_0x5ddfab(0x2a4)],_0x5ddfab(0x2d5),_0x3b7154[_0x5ddfab(0x335)],_0x3b7154['tGfmS'],_0x3b7154[_0x5ddfab(0x456)],_0x3b7154[_0x5ddfab(0x2c1)],_0x3b7154[_0x5ddfab(0x3a4)]];for(let _0x4dfff6=0x0;_0x3b7154[_0x5ddfab(0x40e)](_0x4dfff6,_0x60e9cf['length']);_0x4dfff6++){if(_0x3b7154[_0x5ddfab(0x306)]!==_0x3b7154['loeAh']){const _0x441979=_0x19b694[_0x5ddfab(0x3d2)](_0x3b7154[_0x5ddfab(0x488)]),_0x4f793a=_0x2eff1c[_0x5ddfab(0x3d2)](_0x3b7154[_0x5ddfab(0x28f)]),_0x60ba60=_0x342d94[_0x383c26]['markedForReview'];_0x441979[_0x5ddfab(0x225)]=_0x60ba60?_0x3b7154[_0x5ddfab(0x222)]:_0x3b7154[_0x5ddfab(0x492)],_0x4f793a[_0x5ddfab(0x235)]=_0x60ba60?_0x3b7154[_0x5ddfab(0x3bf)]:_0x3b7154[_0x5ddfab(0x4ac)];}else{const _0x4c090d=_0x38019d[_0x5ddfab(0x4b5)][_0x5ddfab(0x1e7)]['bind'](_0x38019d),_0x110a8c=_0x60e9cf[_0x4dfff6],_0x16a254=_0x478371[_0x110a8c]||_0x4c090d;_0x4c090d['__proto__']=_0x38019d[_0x5ddfab(0x23a)](_0x38019d),_0x4c090d[_0x5ddfab(0x2fd)]=_0x16a254['toString']['bind'](_0x16a254),_0x478371[_0x110a8c]=_0x4c090d;}}});_0x2fb938();let questionsData=[{'text':_0x573d1a(0x463),'choices':[{'id':0x1,'text':_0x573d1a(0x3eb)},{'id':0x2,'text':'Blocking\x20the\x20action\x20of\x20P\x20glycoprotein'},{'id':0x3,'text':_0x573d1a(0x4c0)},{'id':0x4,'text':_0x573d1a(0x1f6)}],'correct_choice_id':0x3,'solution':_0x573d1a(0x1f9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x4b9),'choices':[{'id':0x1,'text':_0x573d1a(0x30a)},{'id':0x2,'text':_0x573d1a(0x4c6)},{'id':0x3,'text':_0x573d1a(0x256)},{'id':0x4,'text':'Nilotinib'}],'correct_choice_id':0x3,'solution':_0x573d1a(0x4ab),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x400),'choices':[{'id':0x1,'text':_0x573d1a(0x3e3)},{'id':0x2,'text':_0x573d1a(0x423)},{'id':0x3,'text':_0x573d1a(0x442)},{'id':0x4,'text':_0x573d1a(0x33d)}],'correct_choice_id':0x1,'solution':'<p>The\x20drug\x20of\x20choice\x20for\x20the\x20management\x20of\x20a\x20patient\x20with\x20a&nbsp;<strong>metastatic\x20gastrointestinal\x20stromal\x20tumor</strong>\x20is\x20<strong>imatinib.&nbsp;</strong></p>\x0a<p>It\x20is\x20an\x20<strong>oral</strong>\x20anticancer\x20drug\x20that\x20acts\x20by\x20<strong>inhibiting\x20tyrosine\x20kinase</strong>\x20activated\x20due\x20to\x20BCR-ABL\x20fusion.\x20It\x20also\x20inhibits\x20other\x20related\x20tyrosine\x20kinases\x20and\x20hence\x20is\x20used\x20in\x20the\x20treatment\x20of\x20conditions\x20like\x20gastrointestinal\x20stromal\x20tumor\x20(driven\x20by\x20a<strong>\x20c-KIT\x20mutation).</strong></p>\x0a<p>Imatinib\x20is\x20the\x20agent\x20of\x20choice\x20for\x20GIST\x20patients\x20with\x20metastatic\x20disease\x20and\x20as\x20adjuvant\x20therapy\x20for\x20c-kit\x20positive\x20GIST.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20with\x20chronic\x20myeloid\x20leukemia\x20was\x20switched\x20to\x20nilotinib\x20as\x20he\x20showed\x20only\x20partial\x20response\x20to\x20imatinib\x20therapy.\x20What\x20is\x20the\x20mechanism\x20resulting\x20in\x20the\x20loss\x20of\x20response?','choices':[{'id':0x1,'text':_0x573d1a(0x34e)},{'id':0x2,'text':_0x573d1a(0x1de)},{'id':0x3,'text':_0x573d1a(0x1fa)},{'id':0x4,'text':_0x573d1a(0x3c9)}],'correct_choice_id':0x3,'solution':_0x573d1a(0x2d8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x417),'choices':[{'id':0x1,'text':_0x573d1a(0x358)},{'id':0x2,'text':'1,\x202\x20and\x204'},{'id':0x3,'text':'1\x20and\x205\x20only'},{'id':0x4,'text':_0x573d1a(0x422)}],'correct_choice_id':0x4,'solution':'<p><strong>Imatinib</strong>\x20is\x20the\x20agent\x20of\x20<strong>choice</strong>\x20in&nbsp;patients\x20with<strong>\x20metastatic\x20GIST</strong>\x20and\x20as\x20<strong>adjuvant</strong>\x20therapy\x20for\x20<strong>c-kit\x20positive</strong>\x20GIST.&nbsp;Imatinib\x20also\x20shows\x20therapeutic\x20benefits\x20in\x20patients\x20with&nbsp;<strong>hypereosinophilia\x20syndrome</strong>\x20and<strong>\x20dermatofibrosarcoma\x20protuberans&nbsp;</strong>(driven\x20by\x20activating\x20mutations\x20in\x20the\x20PDGFR).</p>\x0a<p>Imatinib\x20is\x20an\x20oral\x20anticancer\x20drug\x20that\x20acts\x20by\x20inhibiting\x20tyrosine\x20kinase\x20activated\x20due\x20to\x20ABL-BCR\x20fusion.&nbsp;Imatinib\x20also\x20inhibits\x20other\x20kinases\x20and\x20hence\x20is\x20used\x20in\x20the\x20above-mentioned\x20conditions.</p>\x0a<p><strong\x20class=\x22ng-binding\x22>Indications\x20for\x20imatinib:</strong></p>\x0a<div\x20class=\x22panel-body\x20ng-scope\x22>\x0a<ul>\x0a<li><strong>BCR-ABL\x20kinase\x20mutations:</strong>\x0a<ul>\x0a<li>Chronic\x20myelogenous\x20leukemia\x20(CML)</li>\x0a<li>Acute\x20lymphoblastic\x20leukemia\x20(ALL)</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a<ul>\x0a<li><strong>C-KIT\x20mutations\x20-\x20</strong>gastrointestinal\x20stromal\x20tumors\x20(GIST)</li>\x0a</ul>\x0a<ul>\x0a<li><strong>PDGFR\x20mutations:</strong>\x0a<ul>\x0a<li>Dermatofibrosarcoma\x20protuberans</li>\x0a<li>Hypereosinophilia\x20syndrome</li>\x0a<li>Chronic\x20myelomonocytic\x20leukemia\x20(CML)</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x448),'choices':[{'id':0x1,'text':_0x573d1a(0x1e3)},{'id':0x2,'text':'Bosutinib'},{'id':0x3,'text':_0x573d1a(0x284)},{'id':0x4,'text':_0x573d1a(0x4c6)}],'correct_choice_id':0x3,'solution':_0x573d1a(0x3e4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x253),'choices':[{'id':0x1,'text':_0x573d1a(0x2f7)},{'id':0x2,'text':_0x573d1a(0x2fe)},{'id':0x3,'text':_0x573d1a(0x279)},{'id':0x4,'text':_0x573d1a(0x438)}],'correct_choice_id':0x4,'solution':_0x573d1a(0x2b9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x275),'choices':[{'id':0x1,'text':_0x573d1a(0x3a7)},{'id':0x2,'text':_0x573d1a(0x256)},{'id':0x3,'text':_0x573d1a(0x2fb)},{'id':0x4,'text':'Afatinib'}],'correct_choice_id':0x4,'solution':_0x573d1a(0x265),'explanation_video':'','question_images':[],'explanation_images':[_0x573d1a(0x1fc)]},{'text':_0x573d1a(0x2a3),'choices':[{'id':0x1,'text':'Trastuzumab'},{'id':0x2,'text':_0x573d1a(0x423)},{'id':0x3,'text':_0x573d1a(0x437)},{'id':0x4,'text':_0x573d1a(0x282)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x3b6),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x440),'choices':[{'id':0x1,'text':_0x573d1a(0x423)},{'id':0x2,'text':_0x573d1a(0x2cd)},{'id':0x3,'text':'Aflibercept'},{'id':0x4,'text':_0x573d1a(0x46e)}],'correct_choice_id':0x3,'solution':'<p><strong>Aflibercept</strong>\x20is\x20more\x20effective\x20in\x20<strong>diabetic\x20macular\x20edema</strong>\x20in\x20patients\x20with\x20worse\x20baseline\x20values\x20of\x20visual\x20impairment\x20when\x20compared\x20to\x20bevacizumab\x20and\x20ranibizumab.</p>\x0a<p>All\x20of\x20them\x20are\x20<strong>administered\x20intravitreally</strong>.\x20Clinical\x20trials\x20have\x20shown\x20the\x20advantage\x20of\x20aflibercept\x20over&nbsp;bevacizumab\x20and\x20ranibizumab\x20in\x20visual\x20and\x20anatomic\x20terms\x20at\x20the\x20end\x20of\x20one\x20year.&nbsp;</p>\x0a<p>Ramucirumab\x20which\x20is\x20a\x20monoclonal\x20antibody\x20against\x20VEGFR\x20is\x20not\x20indicated\x20for\x20diabetic\x20macular\x20edema.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x21c),'choices':[{'id':0x1,'text':_0x573d1a(0x1ea)},{'id':0x2,'text':_0x573d1a(0x1f1)},{'id':0x3,'text':_0x573d1a(0x227)},{'id':0x4,'text':_0x573d1a(0x4b4)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x383),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Thalidomide\x20should\x20not\x20be\x20used\x20in\x20which\x20of\x20the\x20following\x20conditions?','choices':[{'id':0x1,'text':_0x573d1a(0x294)},{'id':0x2,'text':_0x573d1a(0x2ee)},{'id':0x3,'text':_0x573d1a(0x314)},{'id':0x4,'text':_0x573d1a(0x1d6)}],'correct_choice_id':0x1,'solution':_0x573d1a(0x349),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x494),'choices':[{'id':0x1,'text':_0x573d1a(0x333)},{'id':0x2,'text':_0x573d1a(0x3b4)},{'id':0x3,'text':_0x573d1a(0x38e)},{'id':0x4,'text':_0x573d1a(0x2a6)}],'correct_choice_id':0x4,'solution':_0x573d1a(0x369),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x24e),'choices':[{'id':0x1,'text':_0x573d1a(0x467)},{'id':0x2,'text':_0x573d1a(0x3f7)},{'id':0x3,'text':_0x573d1a(0x282)},{'id':0x4,'text':_0x573d1a(0x252)}],'correct_choice_id':0x2,'solution':'<p><strong>Bortezomib</strong>\x20is\x20a\x20proteasome\x20inhibitor.</p>\x0a<p>It\x20is\x20a\x20boron-containing\x20<strong>anticancer</strong>\x20drug\x20that\x20covalently\x20binds\x20to\x20the\x20proteasome\x20and\x20<strong>inhibits</strong>\x20its\x20<strong>proteolytic\x20activity</strong>,\x20thereby\x20disrupting\x20many\x20intracellular\x20signaling\x20pathways<strong>.</strong>\x20The\x20most\x20important\x20of\x20these\x20is\x20nuclear\x20factor-&kappa;B\x20(<strong>NF-&kappa;B</strong>)\x20<strong>mediated\x20signaling</strong>.\x20It\x20is\x20indicated\x20in\x20the\x20management\x20of\x20<strong>multiple\x20myeloma</strong>.</p>\x0a<p>Option\x20A:\x20Paclitaxel\x20is\x20a\x20taxane.</p>\x0a<p>Option\x20C:\x20Cetuximab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20the\x20extracellular\x20domain\x20of\x20EGFR.</p>\x0a<p>Option\x20D:\x20Irinotecan\x20is\x20a\x20topoisomerase\x20I\x20inhibitor.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x25a),'choices':[{'id':0x1,'text':_0x573d1a(0x44b)},{'id':0x2,'text':_0x573d1a(0x451)},{'id':0x3,'text':_0x573d1a(0x321)},{'id':0x4,'text':'Tamoxifen'}],'correct_choice_id':0x4,'solution':_0x573d1a(0x3a8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x457),'choices':[{'id':0x1,'text':_0x573d1a(0x282)},{'id':0x2,'text':_0x573d1a(0x351)},{'id':0x3,'text':_0x573d1a(0x23f)},{'id':0x4,'text':_0x573d1a(0x272)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x4d2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20among\x20the\x20following\x20is\x20a\x20cyclin-dependent\x20kinase\x20(CDK)\x204/6\x20inhibitor?','choices':[{'id':0x1,'text':'Ruxolitinib'},{'id':0x2,'text':_0x573d1a(0x267)},{'id':0x3,'text':_0x573d1a(0x496)},{'id':0x4,'text':'Trametinib'}],'correct_choice_id':0x2,'solution':_0x573d1a(0x31f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x255),'choices':[{'id':0x1,'text':_0x573d1a(0x2e4)},{'id':0x2,'text':_0x573d1a(0x483)},{'id':0x3,'text':_0x573d1a(0x3bc)},{'id':0x4,'text':'Ibrutinib'}],'correct_choice_id':0x3,'solution':'<p><strong>Vemurafenib</strong>\x20and\x20<strong>dabrafenib\x20</strong>inhibit\x20V600E\x20mutated\x20<strong>BRAF</strong>\x20present\x20in\x20<strong>melanoma.</strong></p>\x0a<p>Both\x20are\x20indicated\x20in\x20the\x20management\x20of\x20melanoma.&nbsp;</p>\x0a<p>The\x20name\x20<strong>vemuraf</strong>enib\x20is\x20derived\x20from\x20the\x20target\x20<strong>V</strong>600<strong>E</strong>\x20<strong>mu</strong>tated\x20B<strong>RAF</strong>.</p>\x0a<p>Ibrutinib\x20is\x20a\x20Bruton\x20tyrosine\x20kinase\x20inhibitor.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x2e8),'choices':[{'id':0x1,'text':_0x573d1a(0x2e4)},{'id':0x2,'text':'Vismodegib'},{'id':0x3,'text':'Olaparib'},{'id':0x4,'text':_0x573d1a(0x30e)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x3e1),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x24a),'choices':[{'id':0x1,'text':_0x573d1a(0x1f4)},{'id':0x2,'text':_0x573d1a(0x373)},{'id':0x3,'text':_0x573d1a(0x28b)},{'id':0x4,'text':_0x573d1a(0x247)}],'correct_choice_id':0x3,'solution':'<p><strong>Venetoclax</strong>\x20is\x20a\x20small-molecule\x20<strong>inhibitor</strong>\x20of\x20<strong>BCL-2</strong>\x20that\x20is\x20approved\x20for\x20use\x20in\x20<strong>CLL</strong>\x20with\x20a\x2017p\x20deletion.</p>\x0a<p>Overexpression\x20of\x20BCL-2\x20has\x20been\x20demonstrated\x20in\x20CLL\x20cells\x20where\x20it\x20mediates\x20tumor\x20cell\x20survival.&nbsp;Venetoclax\x20helps\x20restore\x20the\x20process\x20of\x20apoptosis\x20by\x20binding\x20directly\x20to\x20the\x20BCL-2\x20protein,\x20displacing\x20proapoptotic\x20proteins\x20like\x20BIM,\x20triggering\x20mitochondrial\x20outer\x20membrane\x20permeabilization\x20and\x20the\x20activation\x20of\x20caspases.</p>\x0a<p>Olaparib\x20and\x20rucaparib\x20are\x20inhibitors\x20of\x20PARP\x20[Poly\x20(ADP-ribose)\x20polymerase]\x20enzymes.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Sipuleucel-T\x20is\x20the\x20first\x20vaccine\x20approved\x20for\x20the\x20treatment\x20of\x20cancer.\x20This\x20vaccine\x20induces\x20an\x20immune\x20response\x20against\x20which\x20of\x20the\x20following?','choices':[{'id':0x1,'text':_0x573d1a(0x454)},{'id':0x2,'text':_0x573d1a(0x491)},{'id':0x3,'text':_0x573d1a(0x1d2)},{'id':0x4,'text':_0x573d1a(0x2ab)}],'correct_choice_id':0x2,'solution':'<p><strong>Sipuleucel-T</strong>\x20is\x20a\x20cell-based\x20approach\x20to\x20<strong>induce</strong>\x20an\x20<strong>immune\x20response</strong>\x20against<strong>\x20prostatic\x20acid\x20phosphatase</strong>\x20(PAP)\x20that\x20is\x20commonly\x20expressed\x20in<strong>\x20prostatic\x20cancer.</strong>\x20It\x20is\x20approved\x20for\x20use\x20in\x20minimally\x20symptomatic,\x20hormone-refractory,\x20metastatic\x20prostate\x20cancer.&nbsp;</p>\x0a<p>Sipuleucel-T\x20preparation\x20is\x20done\x20by\x20isolating\x20a\x20patient\x27s\x20peripheral\x20blood\x20cells\x20by\x20leukapheresis\x20and\x20then\x20exposing\x20them\x20to\x20PAP-GM-CSF\x20(which\x20is\x20a\x20human\x20recombinant\x20protein).\x20When\x20these\x20treated\x20cells\x20are\x20infused\x20to\x20a\x20patient,\x20the\x20APCs\x20present\x20in\x20the\x20blood\x20produces\x20antibodies\x20directed\x20against\x20PAP.</p>\x0a<p>Prostate-specific\x20membrane\x20antigen\x20(PSMA)\x20is\x20a\x20specific\x20prostate\x20epithelial\x20cell\x20membrane\x20antigen,\x20showing\x20increased\x20expression\x20in\x20prostate\x20cancers,\x20which\x20is\x20also\x20a&nbsp;potential\x20target\x20for\x20monoclonal\x20antibody\x20therapy.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x3ff),'choices':[{'id':0x1,'text':_0x573d1a(0x37f)},{'id':0x2,'text':_0x573d1a(0x37c)},{'id':0x3,'text':_0x573d1a(0x302)},{'id':0x4,'text':_0x573d1a(0x3ce)}],'correct_choice_id':0x4,'solution':'<p><strong>Febuxostat\x20</strong>is\x20a\x20uric\x20acid\x20synthesis\x20inhibitor\x20that\x20acts\x20by<strong>\x20inhibiting\x20</strong>the\x20enzyme<strong>\x20xanthine\x20oxidase</strong>&nbsp;and\x20it\x20is\x20indicated\x20in\x20gout\x20management.</p>\x0a<p>Examples\x20of\x20<strong>histone\x20deacetylase\x20inhibitors</strong>\x20are:</p>\x0a<ul>\x0a<li>Vorinostat\x20-\x20cutaneous\x20T\x20cell\x20lymphoma</li>\x0a<li>Belinostat\x20-\x20peripheral\x20T\x20cell\x20lymphoma</li>\x0a<li>Romidepsin\x20-\x20cutaneous/peripheral\x20T\x20cell\x20lymphoma</li>\x0a<li>Panobinostat\x20-\x20multiple\x20myeloma</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x344),'choices':[{'id':0x1,'text':_0x573d1a(0x483)},{'id':0x2,'text':_0x573d1a(0x2e4)},{'id':0x3,'text':'Trametinib'},{'id':0x4,'text':_0x573d1a(0x1e4)}],'correct_choice_id':0x3,'solution':_0x573d1a(0x257),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x3bd),'choices':[{'id':0x1,'text':'Trastuzumab'},{'id':0x2,'text':_0x573d1a(0x397)},{'id':0x3,'text':_0x573d1a(0x4a5)},{'id':0x4,'text':_0x573d1a(0x3c5)}],'correct_choice_id':0x2,'solution':'<p><strong>Tisagenlecleucel\x20</strong>is\x20the\x20first\x20<strong>gene\x20therapy-based\x20treatment</strong>\x20that\x20is\x20approved\x20for\x20use\x20in<strong>\x20acute\x20lymphoblastic\x20leukemia\x20(ALL).</strong></p>\x0a<p>The\x20therapy\x20involves\x20reprogramming\x20a\x20patient&rsquo;s\x20own\x20T-cells\x20with\x20a\x20transgene\x20encoding\x20a\x20chimeric\x20antigen\x20receptor\x20(CAR)\x20to\x20identify\x20and\x20eliminate\x20<strong>CD19-</strong>expressing\x20malignant\x20and\x20normal\x20cells.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x28d),'choices':[{'id':0x1,'text':_0x573d1a(0x3e3)},{'id':0x2,'text':'Dasatinib'},{'id':0x3,'text':_0x573d1a(0x1e3)},{'id':0x4,'text':_0x573d1a(0x30a)}],'correct_choice_id':0x4,'solution':_0x573d1a(0x434),'explanation_video':'','question_images':[_0x573d1a(0x40c)],'explanation_images':[]},{'text':_0x573d1a(0x2da),'choices':[{'id':0x1,'text':_0x573d1a(0x267)},{'id':0x2,'text':_0x573d1a(0x373)},{'id':0x3,'text':_0x573d1a(0x37f)},{'id':0x4,'text':_0x573d1a(0x37c)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x394),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20conditions\x20has\x20hydrogen\x20peroxide\x20been\x20recently\x20approved\x20for?','choices':[{'id':0x1,'text':_0x573d1a(0x2d3)},{'id':0x2,'text':_0x573d1a(0x4ce)},{'id':0x3,'text':_0x573d1a(0x4ae)},{'id':0x4,'text':_0x573d1a(0x41b)}],'correct_choice_id':0x4,'solution':_0x573d1a(0x298),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x461),'choices':[{'id':0x1,'text':'Breast\x20cancer'},{'id':0x2,'text':'Colon\x20cancer'},{'id':0x3,'text':_0x573d1a(0x3f3)},{'id':0x4,'text':'Gastric\x20cancer'}],'correct_choice_id':0x3,'solution':_0x573d1a(0x325),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x2eb),'choices':[{'id':0x1,'text':'Denileukin\x20diftitox'},{'id':0x2,'text':_0x573d1a(0x323)},{'id':0x3,'text':_0x573d1a(0x3e3)},{'id':0x4,'text':_0x573d1a(0x1e3)}],'correct_choice_id':0x2,'solution':_0x573d1a(0x322),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x573d1a(0x3e8),'choices':[{'id':0x1,'text':_0x573d1a(0x43f)},{'id':0x2,'text':_0x573d1a(0x2c9)},{'id':0x3,'text':_0x573d1a(0x2c5)},{'id':0x4,'text':_0x573d1a(0x1d1)}],'correct_choice_id':0x2,'solution':'<p><strong>Denileukin\x20diftitox</strong>\x20is\x20an\x20<strong>immunotoxin</strong>\x20made\x20from\x20the\x20genetic\x20recombination\x20of\x20<strong>IL-2</strong>\x20and\x20the\x20catalytically\x20active\x20fragment\x20of\x20<strong>diphtheria\x20toxin</strong>.&nbsp;</p>\x0a<p>It\x20is\x20indicated\x20for\x20advanced\x20<strong>cutaneous\x20T-cell\x20lymphoma</strong>\x20in\x20patients\x20with\x20&gt;20%\x20of\x20T\x20cells\x20expressing\x20the\x20surface\x20marker\x20CD25.&nbsp;After\x20binding\x20to\x20the\x20IL-2\x20receptors,\x20it\x20is\x20internalized\x20by\x20endocytosis.&nbsp;The\x20active\x20fragment\x20of\x20<strong>diphtheria\x20toxin</strong>\x20then\x20is\x20released\x20into\x20the\x20cytosol,\x20where\x20it\x20<strong>inhibits\x20protein\x20synthesis</strong>\x20through\x20ADP\x20ribosylation,\x20leading\x20to\x20<strong>cell\x20death</strong>.</p>\x0a<p>Immunotoxins\x20are\x20proteins\x20that\x20contain\x20a\x20toxin\x20along\x20with\x20an\x20antibody\x20that\x20binds\x20specifically\x20to\x20target\x20cells.</p>\x0a<p><strong>Antibody-drug\x20conjugates</strong>\x20are\x20complex\x20molecules\x20composed\x20of\x20an&nbsp;antibody&nbsp;linked\x20to\x20a\x20biologically\x20active&nbsp;cytotoxic&nbsp;(anticancer)\x20drug.\x20These\x20antibody-targeted\x20drug\x20therapies\x20are\x20cell-specific\x20to\x20kill\x20efficiently\x20the\x20target\x20cells\x20that\x20bind\x20and\x20internalize\x20the\x20drug\x20conjugate.\x20Examples\x20are:</p>\x0a<dl\x20class=\x22article-list\x22>\x0a<dt></dt>\x0a</dl>\x0a<ul>\x0a<li><strong>Gemtuzumab&nbsp;ozogamicin\x20-&nbsp;</strong>Monoclonal\x20antibody\x20against\x20CD33\x20linked\x20to\x20a\x20semisynthetic\x20derivative\x20of\x20calicheamicin,\x20a\x20potent\x20antitumor\x20antibiotic.&nbsp;It\x20was\x20approved\x20for\x20the\x20treatment\x20of\x20acute\x20myeloid\x20leukemia.</li>\x0a<li\x20class=\x22p1\x22><strong>Brentuximab\x20vedotin\x20-&nbsp;</strong>Anti-CD30\x20IgG1\x20monoclonal\x20antibody\x20linked\x20with\x20the\x20microtubule-disrupting\x20agent\x20MMAE.&nbsp;It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20Hodgkin\x20and\x20anaplastic\x20lymphoma.</li>\x0a<li\x20class=\x22p1\x22><strong>Ado-trastuzumab\x20emtansine\x20-&nbsp;</strong>It<strong>&nbsp;</strong>combines\x20the\x20HER2-targeted\x20properties\x20of\x20trastuzumab\x20with\x20the\x20antimicrotubule\x20agent\x20DM1\x20(derived\x20from\x20maytansine),\x20allowing\x20preferential\x20intracellular\x20drug\x20delivery\x20to\x20HER2+\x20cells.&nbsp;It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20HER+\x20breast\x20cancer.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]}],quizName='67\x20Interleukins,\x20Growth\x20Factors\x20And\x20Targeted\x20Therapies';const quizFilename='67-interleukins-growth-factors-and-targeted-therapies-38ac274f.html';let hierarchy=[_0x573d1a(0x29d),_0x573d1a(0x32d),'Pharmacology'];if(window['location'][_0x573d1a(0x4bb)][_0x573d1a(0x2a1)]('custom_quiz.html')){const customData=JSON['parse'](localStorage[_0x573d1a(0x1f5)]('customQuizData'));customData&&(questionsData=customData[_0x573d1a(0x1dc)],quizName=customData[_0x573d1a(0x4c8)],hierarchy=customData['hierarchy'],document['title']=quizName+_0x573d1a(0x4d1),document[_0x573d1a(0x3d2)](_0x573d1a(0x33f))[_0x573d1a(0x235)]=questionsData[_0x573d1a(0x248)],document[_0x573d1a(0x3d2)](_0x573d1a(0x340))[_0x573d1a(0x235)]=hierarchy['join'](_0x573d1a(0x35c)));}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x573d1a(0x219),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x573d1a(0x30f)](),quizStartTime=Date[_0x573d1a(0x30f)](),isQuizCompleted=![],questionStates=new Array(questionsData['length'])[_0x573d1a(0x40a)](null)['map'](()=>({'status':_0x573d1a(0x458),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x573d1a(0x248)]};function saveProgress(){const _0x1c4d19=_0x573d1a,_0x3d5c1d={'FNozI':_0x1c4d19(0x398),'QHEfv':_0x1c4d19(0x447)};if(isQuizCompleted)return;const _0x103efa=JSON['parse'](localStorage[_0x1c4d19(0x1f5)](_0x1c4d19(0x447)))||{};_0x103efa[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x3d5c1d[_0x1c4d19(0x36b)],'lastSeen':new Date()['toISOString']()},localStorage['setItem'](_0x3d5c1d['QHEfv'],JSON['stringify'](_0x103efa));}function loadProgress(){const _0x1eb9d6=_0x573d1a,_0xcc14e={'ibZnM':_0x1eb9d6(0x1f3),'vKizn':_0x1eb9d6(0x224)},_0x5df799=JSON[_0x1eb9d6(0x470)](localStorage[_0x1eb9d6(0x1f5)](_0x1eb9d6(0x447)))||{},_0xd29280=_0x5df799[quizFilename];if(_0xd29280){if(_0x1eb9d6(0x372)===_0x1eb9d6(0x372))return questionStates=_0xd29280[_0x1eb9d6(0x4a8)],stats=_0xd29280[_0x1eb9d6(0x384)],currentQuestionIndex=_0xd29280[_0x1eb9d6(0x209)],currentMode=_0xd29280[_0x1eb9d6(0x3d7)],console['log'](_0xcc14e[_0x1eb9d6(0x41e)]),!![];else _0x2ed807(_0xcc14e[_0x1eb9d6(0x403)])&&_0x26204d();}return![];}function clearProgress(){const _0x406358=_0x573d1a,_0x46f303={'pHAbF':_0x406358(0x447),'yJtIF':_0x406358(0x27c)},_0x58bd7c=JSON[_0x406358(0x470)](localStorage[_0x406358(0x1f5)](_0x46f303[_0x406358(0x319)]))||{};_0x58bd7c[quizFilename]&&(delete _0x58bd7c[quizFilename],localStorage[_0x406358(0x478)](_0x46f303[_0x406358(0x319)],JSON[_0x406358(0x43e)](_0x58bd7c)),console['log'](_0x46f303[_0x406358(0x2c8)]));}function markQuizAsCompleted(){const _0x1d9c5a=_0x573d1a,_0x300d94={'fnEYQ':_0x1d9c5a(0x447),'OWQsy':_0x1d9c5a(0x45c)},_0x2a700c=JSON['parse'](localStorage[_0x1d9c5a(0x1f5)](_0x300d94['fnEYQ']))||{},_0x4ebbf6=questionsData[_0x1d9c5a(0x248)],_0x53a7e7=stats[_0x1d9c5a(0x283)]||0x0;_0x2a700c[quizFilename]={'score':_0x53a7e7,'total':_0x4ebbf6,'status':_0x300d94[_0x1d9c5a(0x20b)],'completedOn':new Date()['toISOString']()},localStorage[_0x1d9c5a(0x478)](_0x300d94[_0x1d9c5a(0x22e)],JSON[_0x1d9c5a(0x43e)](_0x2a700c));}const urlParams=new URLSearchParams(window['location'][_0x573d1a(0x3d4)]),startAt=parseInt(urlParams[_0x573d1a(0x250)]('startAt')),resume=urlParams[_0x573d1a(0x250)](_0x573d1a(0x48e))==='true';function goBack(){const _0x42ad09=_0x573d1a,_0x14ca0a={'XSGXN':function(_0x3bf155){return _0x3bf155();},'IySwi':'index.html'};if(!isQuizCompleted)_0x14ca0a['XSGXN'](saveProgress);window['location'][_0x42ad09(0x374)]=document[_0x42ad09(0x392)]||_0x14ca0a[_0x42ad09(0x1e1)];}function selectMode(_0x263586){const _0xe399ee=_0x573d1a,_0x2f2d5b={'Dteal':'none','JQAWk':function(_0x23c042){return _0x23c042();}};currentMode=_0x263586,document['getElementById'](_0xe399ee(0x228))[_0xe399ee(0x46c)][_0xe399ee(0x2b4)]=_0x2f2d5b['Dteal'],_0x2f2d5b['JQAWk'](initializeQuiz);}function initializeQuiz(){const _0x528c81=_0x573d1a,_0x2593d3={'lyxyV':_0x528c81(0x300),'RWFDV':'Incorrect','JiXYj':_0x528c81(0x2fa),'mBKAg':_0x528c81(0x2f0),'vkqyf':'testModeReviewLegend','SbOIW':function(_0x5b7e92,_0x46f5a7){return _0x5b7e92===_0x46f5a7;},'SNWtr':_0x528c81(0x30c),'crsDC':function(_0x30c487,_0xdcabbf){return _0x30c487===_0xdcabbf;},'rebes':'timed_exam','fsgTw':_0x528c81(0x2bc),'abcyx':_0x528c81(0x356),'hBnTZ':_0x528c81(0x49b),'aKIRL':_0x528c81(0x2ff),'VXJAU':_0x528c81(0x411),'HfNmO':_0x528c81(0x3f1),'dPaoG':'timed_study','OlgDd':function(_0x420e70,_0x961ea3){return _0x420e70!==_0x961ea3;},'NWehb':_0x528c81(0x48a),'lfPbR':function(_0x506afc,_0x495c03){return _0x506afc(_0x495c03);},'AZhZw':function(_0x20e155,_0x344729){return _0x20e155>=_0x344729;},'eJJVf':function(_0x24580e,_0x2761be){return _0x24580e<_0x2761be;},'gjRYN':function(_0x22682e){return _0x22682e();},'gmCMa':function(_0x9407cb){return _0x9407cb();},'wnSbZ':function(_0x592807){return _0x592807();}};quizStartTime=Date[_0x528c81(0x30f)]();const _0x39e32a=document[_0x528c81(0x3d2)](_0x2593d3[_0x528c81(0x2ef)]),_0x412452=document['getElementById'](_0x2593d3[_0x528c81(0x3a1)]),_0x343c07=document[_0x528c81(0x3d2)](_0x2593d3[_0x528c81(0x425)]),_0x21c145=_0x2593d3[_0x528c81(0x2ac)](currentMode,_0x2593d3[_0x528c81(0x396)])||_0x2593d3[_0x528c81(0x381)](currentMode,_0x2593d3[_0x528c81(0x49e)]);document[_0x528c81(0x3d2)](_0x2593d3[_0x528c81(0x3dd)])[_0x528c81(0x46c)][_0x528c81(0x2b4)]=_0x21c145?'none':_0x2593d3[_0x528c81(0x404)],document[_0x528c81(0x3d2)](_0x2593d3[_0x528c81(0x3da)])['style'][_0x528c81(0x2b4)]=_0x21c145?_0x2593d3['aKIRL']:_0x2593d3[_0x528c81(0x404)],document[_0x528c81(0x3d2)](_0x528c81(0x22f))['style']['display']=_0x21c145?_0x528c81(0x356):_0x2593d3[_0x528c81(0x387)],document['getElementById'](_0x2593d3['VXJAU'])[_0x528c81(0x46c)][_0x528c81(0x2b4)]=_0x21c145?_0x2593d3[_0x528c81(0x404)]:_0x2593d3['aKIRL'],_0x39e32a['style'][_0x528c81(0x2b4)]=_0x21c145?_0x2593d3['aKIRL']:_0x2593d3[_0x528c81(0x290)],_0x412452[_0x528c81(0x46c)][_0x528c81(0x2b4)]=_0x21c145?_0x2593d3['HfNmO']:_0x2593d3[_0x528c81(0x387)],_0x343c07[_0x528c81(0x46c)][_0x528c81(0x2b4)]=_0x21c145?_0x2593d3[_0x528c81(0x290)]:_0x2593d3[_0x528c81(0x387)],(currentMode===_0x2593d3[_0x528c81(0x4d0)]||currentMode===_0x2593d3[_0x528c81(0x49e)])&&(_0x2593d3['OlgDd'](_0x2593d3[_0x528c81(0x1ff)],_0x2593d3[_0x528c81(0x1ff)])?(_0x3b2a2a=_0x2593d3[_0x528c81(0x3b5)],_0x58d77e=_0x2593d3[_0x528c81(0x327)]):document[_0x528c81(0x3d2)](_0x528c81(0x239))['classList']['remove'](_0x528c81(0x43a))),!_0x2593d3[_0x528c81(0x3cd)](isNaN,startAt)&&_0x2593d3[_0x528c81(0x23d)](startAt,0x0)&&_0x2593d3[_0x528c81(0x241)](startAt,questionsData[_0x528c81(0x248)])&&(currentQuestionIndex=startAt),loadBookmarkedQuestions(),_0x2593d3[_0x528c81(0x3ec)](generateQuestionNav),_0x2593d3[_0x528c81(0x25d)](updateStats),_0x2593d3[_0x528c81(0x24b)](displayQuestion);}function _0x2a41(_0x34881e,_0x5c55b4){const _0x57cdb2=_0x50fb();return _0x2a41=function(_0x2fb938,_0x38019d){_0x2fb938=_0x2fb938-0x1d0;let _0x31b1bf=_0x57cdb2[_0x2fb938];return _0x31b1bf;},_0x2a41(_0x34881e,_0x5c55b4);}function generateQuestionNav(){const _0x4c8692=_0x573d1a,_0x149067={'iNOoi':_0x4c8692(0x4b8),'tfBDJ':function(_0x5cb4b4,_0x55ee65){return _0x5cb4b4<_0x55ee65;},'TDHZJ':_0x4c8692(0x342),'qblHb':'w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','sxuwm':function(_0x55474c){return _0x55474c();}},_0x32be1f=document[_0x4c8692(0x3d2)](_0x149067[_0x4c8692(0x3b2)]);_0x32be1f[_0x4c8692(0x324)]='';for(let _0x3ba245=0x0;_0x149067[_0x4c8692(0x202)](_0x3ba245,questionsData[_0x4c8692(0x248)]);_0x3ba245++){const _0x580116=document['createElement'](_0x149067['TDHZJ']);_0x580116[_0x4c8692(0x235)]=_0x3ba245+0x1,_0x580116['className']=_0x149067['qblHb'],_0x580116[_0x4c8692(0x3e2)]=()=>jumpToQuestion(_0x3ba245),_0x580116['id']=_0x4c8692(0x45b)+_0x3ba245,_0x32be1f[_0x4c8692(0x207)](_0x580116);}_0x149067[_0x4c8692(0x2d6)](updateQuestionNav);}function updateQuestionNav(){const _0xb06306=_0x573d1a,_0xfc2b85={'WebFT':function(_0x474597,_0x9c8e28){return _0x474597!==_0x9c8e28;},'sAphA':_0xb06306(0x3c6),'EHDbi':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','lBKQQ':_0xb06306(0x2fa),'kOWmD':_0xb06306(0x493),'YUpvB':_0xb06306(0x3ba),'yEEJI':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','lVGns':_0xb06306(0x292),'VQUwe':_0xb06306(0x4a6),'HVXtI':function(_0x3b6a1f,_0x385d2d){return _0x3b6a1f===_0x385d2d;},'eNeaG':_0xb06306(0x2ec),'UGdrS':_0xb06306(0x497),'VeyfG':_0xb06306(0x443),'TzgAG':function(_0x6297bb,_0x9874f9){return _0x6297bb===_0x9874f9;},'FVxIG':'DWsIM','eAonZ':_0xb06306(0x4a3),'caIMV':_0xb06306(0x452),'UKQNV':_0xb06306(0x42c),'SLYKX':function(_0x410c09,_0x356bd0){return _0x410c09===_0x356bd0;},'OUiqg':_0xb06306(0x300),'dyrtZ':_0xb06306(0x382),'psNro':function(_0x44b2c4,_0x48782f){return _0x44b2c4!==_0x48782f;}};for(let _0x5ca276=0x0;_0x5ca276<questionsData[_0xb06306(0x248)];_0x5ca276++){const _0xc0d568=document['getElementById'](_0xb06306(0x45b)+_0x5ca276),_0x36179e=questionStates[_0x5ca276];let _0x10a143='';if(_0x5ca276===currentQuestionIndex){if(_0xfc2b85['HVXtI'](_0xfc2b85['eNeaG'],_0xb06306(0x2ec)))_0x10a143=_0xfc2b85[_0xb06306(0x39a)];else{if(_0xfc2b85[_0xb06306(0x3c8)](_0x4b1ac0[_0xb06306(0x201)],null))_0xc8faa7=_0xfc2b85[_0xb06306(0x289)];else _0xc6d229=_0xfc2b85[_0xb06306(0x479)];}}else{if(_0x36179e[_0xb06306(0x485)])_0x10a143=_0xfc2b85[_0xb06306(0x308)];else{if(_0x36179e[_0xb06306(0x40b)]){if(_0xfc2b85[_0xb06306(0x31b)](_0xb06306(0x25c),_0xfc2b85[_0xb06306(0x1ee)]))_0x10a143='nav-btn-marked-review';else{const _0x4713bd=_0x57e0c6[_0xb06306(0x3d2)](_0xfc2b85['lBKQQ']),_0x465031=_0x2467ad[_0xb06306(0x3d2)](_0xfc2b85[_0xb06306(0x486)]),_0x289223=_0x4a9f5b[_0x12353c]['bookmarked'];_0x4713bd[_0xb06306(0x225)]=_0x289223?_0xfc2b85['YUpvB']:_0xfc2b85[_0xb06306(0x3fd)],_0x465031[_0xb06306(0x235)]=_0x289223?_0xfc2b85[_0xb06306(0x3d0)]:_0xfc2b85[_0xb06306(0x4b3)];}}else{if(_0xfc2b85[_0xb06306(0x31b)](currentMode,_0xb06306(0x219))||currentMode===_0xfc2b85['eAonZ']){if(_0x36179e[_0xb06306(0x477)]===_0xfc2b85[_0xb06306(0x465)])_0x10a143=_0xfc2b85['UKQNV'];else{if(_0xfc2b85[_0xb06306(0x406)](_0x36179e[_0xb06306(0x477)],_0xfc2b85[_0xb06306(0x285)]))_0x10a143=_0xfc2b85[_0xb06306(0x2e7)];else _0x10a143=_0xfc2b85[_0xb06306(0x479)];}}else{if(_0xfc2b85[_0xb06306(0x4be)](_0x36179e['selectedAnswer'],null))_0x10a143=_0xb06306(0x3c6);else _0x10a143=_0xfc2b85[_0xb06306(0x479)];}}}}_0xc0d568[_0xb06306(0x225)]=_0xb06306(0x29e)+_0x10a143;}}function jumpToQuestion(_0x178399){const _0x26968e=_0x573d1a,_0x5b2654={'QMNsS':function(_0x221211,_0xc6d978){return _0x221211!==_0xc6d978;},'BNrSx':'hKlxR','rpBsw':_0x26968e(0x3aa),'tmDqy':function(_0x43d44b,_0x32acc1){return _0x43d44b-_0x32acc1;},'nGeNy':function(_0x42d64f){return _0x42d64f();}};_0x178399>=0x0&&_0x178399<questionsData[_0x26968e(0x248)]&&(_0x5b2654[_0x26968e(0x2f5)](_0x5b2654['BNrSx'],_0x5b2654[_0x26968e(0x2f9)])?(questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x5b2654[_0x26968e(0x4c4)](Date['now'](),questionStartTime)),currentQuestionIndex=_0x178399,_0x5b2654[_0x26968e(0x49c)](displayQuestion),saveProgress()):_0x5f124e());}function updateStats(){const _0x16485e=_0x573d1a,_0x4217e2={'mHTJZ':function(_0x36b586,_0x2dc06e){return _0x36b586===_0x2dc06e;},'dMURC':'study','yCcFw':function(_0x534ddd,_0x2e48b5){return _0x534ddd===_0x2e48b5;},'TymmY':'timed_study','SOuMh':_0x16485e(0x38f),'QrHzY':_0x16485e(0x480),'HCVzN':_0x16485e(0x42e),'PHkyc':function(_0x19f61b,_0x1857be){return _0x19f61b>_0x1857be;},'udjeW':function(_0x3488a6,_0xddd4b2){return _0x3488a6/_0xddd4b2;},'RHOhB':_0x16485e(0x36f),'Vjpfe':function(_0x1adaa5,_0x4a2b67){return _0x1adaa5+_0x4a2b67;},'dCsbu':function(_0x22e9e9,_0x152d55){return _0x22e9e9/_0x152d55;},'Zlfrw':function(_0x1ab946,_0x2a4aae){return _0x1ab946%_0x2a4aae;},'RqaRD':_0x16485e(0x39f),'ubklG':function(_0xfa32be,_0x1f6a81){return _0xfa32be+_0x1f6a81;}};if(_0x4217e2[_0x16485e(0x402)](currentMode,_0x4217e2[_0x16485e(0x310)])||_0x4217e2[_0x16485e(0x365)](currentMode,_0x4217e2['TymmY'])){document['getElementById'](_0x4217e2['SOuMh'])['textContent']=stats['correctAnswers'],document[_0x16485e(0x3d2)](_0x4217e2[_0x16485e(0x2cc)])[_0x16485e(0x235)]=stats[_0x16485e(0x258)],document[_0x16485e(0x3d2)](_0x4217e2[_0x16485e(0x3af)])['textContent']=stats[_0x16485e(0x42e)];const _0x3e24ce=_0x4217e2[_0x16485e(0x35e)](stats['totalAttempted'],0x0)?Math['round'](_0x4217e2[_0x16485e(0x29a)](stats[_0x16485e(0x283)],stats[_0x16485e(0x42e)])*0x64):0x0;document[_0x16485e(0x3d2)](_0x4217e2[_0x16485e(0x212)])[_0x16485e(0x235)]=_0x4217e2['Vjpfe'](_0x3e24ce,'%'),stats['totalTime']=questionStates[_0x16485e(0x380)]((_0x38ed27,_0x75a779)=>_0x38ed27+_0x75a779[_0x16485e(0x39f)],0x0);const _0x3b3cb0=Math[_0x16485e(0x445)](_0x4217e2['udjeW'](stats['totalTime'],0x3e8)),_0x9eea8c=Math[_0x16485e(0x445)](_0x4217e2[_0x16485e(0x32b)](_0x3b3cb0,0x3c)),_0xcd12b3=_0x4217e2[_0x16485e(0x1e8)](_0x3b3cb0,0x3c);document[_0x16485e(0x3d2)](_0x4217e2[_0x16485e(0x363)])['textContent']=_0x4217e2[_0x16485e(0x328)](_0x9eea8c+':',_0xcd12b3[_0x16485e(0x2fd)]()[_0x16485e(0x2bb)](0x2,'0'));}}function setupVideo(_0x3f05ea,_0x2f4bea){const _0x580e3a=_0x573d1a,_0x4b3eff={'FNDBr':_0x580e3a(0x3f1),'JwHrN':'pLZwx','mpDZS':'application/vnd.apple.mpegurl'};if(Hls[_0x580e3a(0x21e)]()){if(_0x4b3eff[_0x580e3a(0x361)]!==_0x4b3eff[_0x580e3a(0x361)])_0x2cbf9b(),_0x3ddbf4['getElementById'](_0x580e3a(0x228))[_0x580e3a(0x46c)]['display']=_0x4b3eff['FNDBr'];else{const _0x1e6df7=new Hls();_0x1e6df7[_0x580e3a(0x366)](_0x2f4bea),_0x1e6df7[_0x580e3a(0x262)](_0x3f05ea);}}else _0x3f05ea[_0x580e3a(0x42f)](_0x4b3eff[_0x580e3a(0x3ef)])&&(_0x3f05ea[_0x580e3a(0x3ca)]=_0x2f4bea);}function displayQuestion(){const _0x46c4ee=_0x573d1a,_0x1b047c={'mjEPv':_0x46c4ee(0x266),'jucCB':_0x46c4ee(0x224),'tPwno':function(_0x9d3664,_0x2c9a16){return _0x9d3664!==_0x2c9a16;},'cRenQ':_0x46c4ee(0x38a),'OGyNg':_0x46c4ee(0x47f),'CBfzK':function(_0x2c8d00,_0x4b4d15){return _0x2c8d00+_0x4b4d15;},'FgMjx':_0x46c4ee(0x1f0),'LMssu':function(_0xc9ab51,_0x110c02){return _0xc9ab51!==_0x110c02;},'eKllO':_0x46c4ee(0x2af),'HcxPL':'div','BntTk':_0x46c4ee(0x245),'CMbVH':function(_0x282653,_0x46ca44){return _0x282653+_0x46ca44;},'BHsEb':_0x46c4ee(0x390),'NDOXM':function(_0x36e4c4,_0x14c650){return _0x36e4c4+_0x14c650;},'bsvRd':_0x46c4ee(0x34a),'MXwHP':function(_0x141e98,_0x3a8ffb){return _0x141e98<=_0x3a8ffb;},'wvhNn':function(_0x103fc2,_0x3aef3c){return _0x103fc2(_0x3aef3c);},'zZfUY':function(_0x2e7ccc,_0x254117){return _0x2e7ccc===_0x254117;},'RvBRx':_0x46c4ee(0x367),'ZAVRT':function(_0x24bb9a){return _0x24bb9a();},'eXXRB':_0x46c4ee(0x3e7),'SeaaQ':_0x46c4ee(0x208),'eBfTI':_0x46c4ee(0x261),'WgPqG':_0x46c4ee(0x3ac),'LpyhR':_0x46c4ee(0x480),'qlxoH':_0x46c4ee(0x42e),'ctOWm':function(_0x3a8df6,_0x32e97a){return _0x3a8df6*_0x32e97a;},'GjZBn':function(_0x587edc,_0x111838){return _0x587edc/_0x111838;},'cRWfF':'accuracy','YHNnX':function(_0x34936e,_0x372053){return _0x34936e/_0x372053;},'IaNtf':function(_0x4a857c,_0x163748){return _0x4a857c%_0x163748;},'bIoIs':_0x46c4ee(0x39f),'ljlNF':function(_0x193bd1,_0x5ecb25){return _0x193bd1+_0x5ecb25;},'kWbwL':_0x46c4ee(0x431),'nVXjm':_0x46c4ee(0x471),'vTtpN':function(_0x2365b5,_0x111429){return _0x2365b5/_0x111429;},'aRvvh':function(_0x36218b,_0x3e5849){return _0x36218b+_0x3e5849;},'SIMwe':_0x46c4ee(0x391),'rpHHP':function(_0x483d67,_0x7c8f){return _0x483d67+_0x7c8f;},'sRWOF':function(_0x27ef3f,_0x5b8d4c){return _0x27ef3f+_0x5b8d4c;},'xeqsJ':'prevBtn','OeTqS':_0x46c4ee(0x43a),'ktUYo':_0x46c4ee(0x46a),'ttKNY':function(_0x23906f,_0x539ab7){return _0x23906f===_0x539ab7;},'VuMwt':_0x46c4ee(0x368),'kYLDX':_0x46c4ee(0x3ab),'ljfho':_0x46c4ee(0x2aa),'ykieF':_0x46c4ee(0x3a6),'zZveU':function(_0x86a054){return _0x86a054();},'juXiz':_0x46c4ee(0x4a3),'SrdYl':_0x46c4ee(0x39c)};if(!questionsData||_0x1b047c[_0x46c4ee(0x30d)](questionsData[_0x46c4ee(0x248)],0x0)){document[_0x46c4ee(0x3d2)](_0x1b047c[_0x46c4ee(0x2b8)])[_0x46c4ee(0x324)]=_0x1b047c[_0x46c4ee(0x427)];return;};const _0x4a96aa=questionsData[currentQuestionIndex];questionStartTime=Date[_0x46c4ee(0x30f)](),selectedOption=questionStates[currentQuestionIndex][_0x46c4ee(0x201)];const _0x43babe=_0x1b047c[_0x46c4ee(0x3fc)](_0x1b047c['vTtpN'](_0x1b047c[_0x46c4ee(0x495)](currentQuestionIndex,0x1),questionsData['length']),0x64);document[_0x46c4ee(0x3d2)](_0x1b047c[_0x46c4ee(0x466)])[_0x46c4ee(0x46c)][_0x46c4ee(0x44c)]=_0x1b047c[_0x46c4ee(0x2a5)](_0x43babe,'%'),document['getElementById'](_0x46c4ee(0x3c3))[_0x46c4ee(0x235)]=_0x1b047c[_0x46c4ee(0x444)](currentQuestionIndex,0x1),updateQuestionNav(),document['getElementById'](_0x1b047c['xeqsJ'])[_0x46c4ee(0x472)]=_0x1b047c[_0x46c4ee(0x30d)](currentQuestionIndex,0x0),document[_0x46c4ee(0x3d2)](_0x46c4ee(0x277))['classList'][_0x46c4ee(0x490)](_0x1b047c[_0x46c4ee(0x23b)]),document['getElementById'](_0x1b047c[_0x46c4ee(0x2b8)])[_0x46c4ee(0x324)]=_0x4a96aa['text']||_0x1b047c[_0x46c4ee(0x3f0)];let _0x7a63ea='';if(_0x4a96aa[_0x46c4ee(0x370)])_0x7a63ea+=_0x46c4ee(0x2d0)+_0x4a96aa[_0x46c4ee(0x370)]+_0x46c4ee(0x2ba);if(_0x4a96aa[_0x46c4ee(0x27b)])_0x7a63ea+=_0x46c4ee(0x33c)+_0x4a96aa[_0x46c4ee(0x27b)]+_0x46c4ee(0x475);_0x4a96aa[_0x46c4ee(0x33a)]&&(_0x1b047c[_0x46c4ee(0x4c3)](_0x1b047c[_0x46c4ee(0x38d)],_0x46c4ee(0x338))?_0x15d6da[_0x46c4ee(0x2bf)](_0x46c4ee(0x46f)):_0x4a96aa[_0x46c4ee(0x33a)]['forEach'](_0x251361=>{const _0x3e00d3=_0x46c4ee;if(_0x1b047c[_0x3e00d3(0x49a)](_0x1b047c['cRenQ'],_0x1b047c[_0x3e00d3(0x32a)])){if(_0x251361)_0x7a63ea+=_0x3e00d3(0x28c)+_0x251361+_0x3e00d3(0x2b6);}else{const _0x12f500=_0x1b047c[_0x3e00d3(0x3ad)][_0x3e00d3(0x4a2)]('|');let _0x3780d1=0x0;while(!![]){switch(_0x12f500[_0x3780d1++]){case'0':_0x452e65['log'](_0x1b047c[_0x3e00d3(0x293)]);continue;case'1':_0x342199=_0x152646[_0x3e00d3(0x3d7)];continue;case'2':_0x1b704e=_0xafdb76[_0x3e00d3(0x4a8)];continue;case'3':_0x4d6d89=_0x3b4181[_0x3e00d3(0x209)];continue;case'4':return!![];case'5':_0x23ae37=_0x58ef4c[_0x3e00d3(0x384)];continue;}break;}}}));document[_0x46c4ee(0x3d2)](_0x1b047c[_0x46c4ee(0x45d)])[_0x46c4ee(0x324)]=_0x7a63ea;const _0x2061f9=document[_0x46c4ee(0x3d2)](_0x1b047c[_0x46c4ee(0x27e)]);_0x2061f9[_0x46c4ee(0x324)]='',_0x2061f9[_0x46c4ee(0x316)][_0x46c4ee(0x2cf)](_0x46c4ee(0x297));if(_0x4a96aa['choices']&&Array['isArray'](_0x4a96aa['choices'])){if(_0x1b047c['ykieF']===_0x1b047c[_0x46c4ee(0x2dc)])_0x4a96aa['choices'][_0x46c4ee(0x38c)]((_0x11a190,_0x38e0d0)=>{const _0x38040d=_0x46c4ee,_0x4a34cd={'VRUOj':function(_0x4fd41b,_0xa98615){const _0x29f7ed=_0x2a41;return _0x1b047c[_0x29f7ed(0x3b3)](_0x4fd41b,_0xa98615);},'iAUaI':_0x1b047c[_0x38040d(0x416)]};if(_0x1b047c[_0x38040d(0x393)](_0x38040d(0x2af),_0x1b047c[_0x38040d(0x1d9)])){const _0x28c994=_0x1d46a3[_0x38040d(0x2cb)](_0x38040d(0x342));_0x28c994[_0x38040d(0x235)]=_0x4a34cd[_0x38040d(0x1d4)](_0x336b24,0x1),_0x28c994[_0x38040d(0x225)]=_0x4a34cd[_0x38040d(0x31e)],_0x28c994[_0x38040d(0x3e2)]=()=>_0x14ab66(_0x579041),_0x28c994['id']=_0x38040d(0x45b)+_0x51a4f6,_0x58e3fa[_0x38040d(0x207)](_0x28c994);}else{const _0xaeddea=String[_0x38040d(0x2e6)](0x41+_0x38e0d0),_0x5b493a=selectedOption===_0x38e0d0,_0x282bfc=document['createElement'](_0x1b047c[_0x38040d(0x399)]);_0x282bfc['innerHTML']='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20'+(_0x5b493a?_0x1b047c[_0x38040d(0x20e)]:'')+_0x38040d(0x24f)+_0x38e0d0+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0xaeddea+_0x38040d(0x3c4)+(_0x11a190['text']||_0x1b047c[_0x38040d(0x291)](_0x1b047c[_0x38040d(0x352)],_0x1b047c['NDOXM'](_0x38e0d0,0x1)))+_0x38040d(0x4cf),_0x2061f9[_0x38040d(0x207)](_0x282bfc);}}),_0x2061f9[_0x46c4ee(0x36c)](_0x46c4ee(0x21f),function(_0x4c9126){const _0xdb6065=_0x46c4ee,_0x170bab={'GuVZf':function(_0x19fdc5){return _0x19fdc5();},'EfhNz':function(_0x136684,_0x37b872){const _0x37f0fd=_0x2a41;return _0x1b047c[_0x37f0fd(0x484)](_0x136684,_0x37b872);},'PhZfP':function(_0x4ec499,_0x464a04){const _0x23f13c=_0x2a41;return _0x1b047c[_0x23f13c(0x409)](_0x4ec499,_0x464a04);},'HLMjI':function(_0x14ddc1,_0x2a1273){const _0x5d7f2b=_0x2a41;return _0x1b047c[_0x5d7f2b(0x30d)](_0x14ddc1,_0x2a1273);},'zeCiA':_0x1b047c[_0xdb6065(0x3f4)],'jFspc':function(_0x51bece){return _0x1b047c['ZAVRT'](_0x51bece);},'lYGHX':function(_0x9e9eb5){return _0x9e9eb5();}};if(_0x1b047c['LMssu'](_0x1b047c[_0xdb6065(0x45f)],_0x1b047c[_0xdb6065(0x1f7)])){const _0xe75ba7=_0x4c9126[_0xdb6065(0x303)][_0xdb6065(0x353)](_0xdb6065(0x221));if(_0xe75ba7){if(_0x1b047c[_0xdb6065(0x30d)](_0x1b047c[_0xdb6065(0x211)],_0x1b047c[_0xdb6065(0x211)])){const _0x68dc7e=_0x1b047c[_0xdb6065(0x409)](parseInt,_0xe75ba7[_0xdb6065(0x389)](_0x1b047c['WgPqG']));selectOption(_0x68dc7e);}else _0x27763b--,_0x170bab[_0xdb6065(0x487)](_0x3cb997),_0x170bab['EfhNz'](_0x54e1ea,0x0)&&(_0x170bab[_0xdb6065(0x1df)](_0x23c1e5,_0x385547),_0x170bab[_0xdb6065(0x311)](_0x344863,_0x170bab[_0xdb6065(0x43b)])?_0x170bab['jFspc'](_0x3f7edf):_0x170bab[_0xdb6065(0x3e9)](_0x118652));}}else _0xcc956e=_0x1b047c[_0xdb6065(0x41f)];});else{const _0x5ae707={'quizName':_0x11392e,'quizFile':_0x3c11b6['location'][_0x46c4ee(0x4bb)]['split']('/')[_0x46c4ee(0x2a8)](),'questionIndex':_0x36630d,'question':_0x4b6193[_0x522db3],'hierarchy':_0x569ffc,'timestamp':_0x59e728['now']()};_0x1d7288['push'](_0x5ae707);}}_0x1b047c[_0x46c4ee(0x3a3)](updateBookmarkButton),_0x1b047c[_0x46c4ee(0x3a3)](updateMarkReviewButton);if((_0x1b047c[_0x46c4ee(0x30d)](currentMode,_0x1b047c[_0x46c4ee(0x2ed)])||_0x1b047c[_0x46c4ee(0x30d)](currentMode,'timed_exam'))&&!isQuizCompleted){if(_0x1b047c['SrdYl']===_0x1b047c[_0x46c4ee(0x412)])_0x1b047c[_0x46c4ee(0x3be)](startTimer);else{_0x3c3c73[_0x46c4ee(0x3d2)](_0x46c4ee(0x38f))[_0x46c4ee(0x235)]=_0x1bf152[_0x46c4ee(0x283)],_0xc227fa['getElementById'](_0x1b047c['LpyhR'])[_0x46c4ee(0x235)]=_0x47d838[_0x46c4ee(0x258)],_0x5074ac['getElementById'](_0x1b047c[_0x46c4ee(0x3f5)])[_0x46c4ee(0x235)]=_0x1b3f5e[_0x46c4ee(0x42e)];const _0x309540=_0x30de5b[_0x46c4ee(0x42e)]>0x0?_0x57a323[_0x46c4ee(0x455)](_0x1b047c['ctOWm'](_0x1b047c[_0x46c4ee(0x2ea)](_0x1292b2[_0x46c4ee(0x283)],_0xf02cfc[_0x46c4ee(0x42e)]),0x64)):0x0;_0x51c4b1['getElementById'](_0x1b047c[_0x46c4ee(0x320)])[_0x46c4ee(0x235)]=_0x1b047c['NDOXM'](_0x309540,'%'),_0x2236d5['totalTime']=_0x2c05e5['reduce']((_0x45e0b7,_0x46f029)=>_0x45e0b7+_0x46f029[_0x46c4ee(0x39f)],0x0);const _0x1b1da5=_0x1e6f1e['floor'](_0x1b047c[_0x46c4ee(0x2ea)](_0x54f505['totalTime'],0x3e8)),_0x382b09=_0x36453e['floor'](_0x1b047c[_0x46c4ee(0x326)](_0x1b1da5,0x3c)),_0x1c85d8=_0x1b047c[_0x46c4ee(0x204)](_0x1b1da5,0x3c);_0x171704['getElementById'](_0x1b047c[_0x46c4ee(0x254)])[_0x46c4ee(0x235)]=_0x1b047c['ljlNF'](_0x382b09,':')+_0x1c85d8[_0x46c4ee(0x2fd)]()[_0x46c4ee(0x2bb)](0x2,'0');}}}function selectOption(_0x1df047){const _0x3454c9=_0x573d1a,_0x59d57a={'tFfVR':function(_0x1af993,_0x1c0902){return _0x1af993===_0x1c0902;},'VkHou':'optionsContainer','Tmcqw':'answered','eQwNr':function(_0x4f33aa,_0x1e7058){return _0x4f33aa-_0x1e7058;},'mXiBH':_0x3454c9(0x221),'jVIUL':_0x3454c9(0x219),'hVTpe':_0x3454c9(0x4a3),'xeKmp':_0x3454c9(0x36e),'QYXaJ':function(_0x4abcee){return _0x4abcee();},'boHqw':'not_attempted','SwSQY':function(_0x41d0ba){return _0x41d0ba();}},_0x270ec4=document[_0x3454c9(0x3d2)](_0x59d57a[_0x3454c9(0x42b)]);if(_0x270ec4['classList'][_0x3454c9(0x223)](_0x59d57a[_0x3454c9(0x233)]))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x3454c9(0x39f)]+=_0x59d57a[_0x3454c9(0x317)](Date[_0x3454c9(0x30f)](),questionStartTime),questionStartTime=Date['now']()),selectedOption=_0x1df047,questionStates[currentQuestionIndex]['selectedAnswer']=_0x1df047,document[_0x3454c9(0x1da)](_0x59d57a[_0x3454c9(0x346)])[_0x3454c9(0x38c)]((_0x285fe1,_0x5e16a3)=>{const _0x424453=_0x3454c9;_0x285fe1[_0x424453(0x316)][_0x424453(0x2dd)](_0x424453(0x245),_0x59d57a['tFfVR'](_0x5e16a3,_0x1df047));}),currentMode===_0x59d57a[_0x3454c9(0x334)]||_0x59d57a[_0x3454c9(0x34d)](currentMode,_0x59d57a[_0x3454c9(0x35d)])?_0x59d57a['tFfVR'](_0x3454c9(0x36e),_0x59d57a[_0x3454c9(0x2de)])?_0x59d57a[_0x3454c9(0x441)](processAnswer):_0x4953a5=_0x561ab7:(questionStates[currentQuestionIndex][_0x3454c9(0x477)]===_0x59d57a[_0x3454c9(0x45e)]&&(questionStates[currentQuestionIndex][_0x3454c9(0x477)]=_0x59d57a[_0x3454c9(0x233)],stats[_0x3454c9(0x42e)]++,stats[_0x3454c9(0x419)]--),_0x59d57a[_0x3454c9(0x4d5)](updateQuestionNav)),_0x59d57a['SwSQY'](saveProgress);}function processAnswer(){const _0x269a15=_0x573d1a,_0x3c1892={'aXKzD':'selected','BWRas':_0x269a15(0x452),'HbJsA':_0x269a15(0x300),'CAOPl':function(_0x15d5b9,_0x1f93b4){return _0x15d5b9===_0x1f93b4;},'YaDVk':function(_0x3dd33b,_0x1f9980){return _0x3dd33b===_0x1f9980;},'dqUin':function(_0x2da2dc,_0x10ef2f){return _0x2da2dc===_0x10ef2f;},'bmCqh':function(_0x4e236f,_0x167027){return _0x4e236f===_0x167027;},'JyqRB':_0x269a15(0x23c),'EUZQE':function(_0x467dda){return _0x467dda();},'khSho':function(_0x3b2504,_0x49a3d8){return _0x3b2504(_0x49a3d8);}},_0x4ed03e=questionsData[currentQuestionIndex],_0xe34e9b=_0x4ed03e[_0x269a15(0x4a9)];if(_0x3c1892[_0x269a15(0x216)](selectedOption,null))return;const _0xdc6919=_0x4ed03e[_0x269a15(0x331)][selectedOption],_0x180879=_0x3c1892['YaDVk'](_0xdc6919['id'],_0xe34e9b);if(_0x3c1892[_0x269a15(0x339)](questionStates[currentQuestionIndex][_0x269a15(0x477)],'not_attempted')){if(_0x3c1892[_0x269a15(0x205)]('qSWLG',_0x3c1892[_0x269a15(0x299)])){_0x1c177d[_0x269a15(0x316)][_0x269a15(0x2cf)](_0x3c1892[_0x269a15(0x47a)]);if(_0x165063===_0x282ae3)_0x127ffe[_0x269a15(0x316)][_0x269a15(0x490)](_0x3c1892['BWRas']);else{if(_0xf57f97===_0x295836&&!_0x5c9a3c)_0x312cc4[_0x269a15(0x316)]['add'](_0x3c1892[_0x269a15(0x3c7)]);}}else{stats[_0x269a15(0x42e)]++,stats['notAttempted']--;if(_0x180879)stats[_0x269a15(0x283)]++;else stats[_0x269a15(0x258)]++;}}questionStates[currentQuestionIndex]['status']=_0x180879?_0x3c1892['BWRas']:_0x269a15(0x300),_0x3c1892['EUZQE'](updateStats),_0x3c1892['khSho'](showInlineFeedback,_0x180879),_0x3c1892['EUZQE'](updateQuestionNav);}function showInlineFeedback(_0x2c3219){const _0x3032b3=_0x573d1a,_0x11e5c5={'vpYmr':'flex','bMWne':function(_0x151d54,_0x542b7f){return _0x151d54===_0x542b7f;},'YjsbX':_0x3032b3(0x1e5),'BQmay':_0x3032b3(0x48b),'uOmpw':_0x3032b3(0x245),'ZNrFj':_0x3032b3(0x452),'vhKwP':'incorrect','OfPaZ':function(_0x6ff1c8,_0x48c57a){return _0x6ff1c8!==_0x48c57a;},'hrTvj':_0x3032b3(0x219),'ZMHob':function(_0x35db38,_0x430c50){return _0x35db38!==_0x430c50;},'zNhoC':_0x3032b3(0x221),'VdaYC':_0x3032b3(0x297),'DGgtX':function(_0x2b8d78){return _0x2b8d78();}};if(_0x11e5c5[_0x3032b3(0x426)](currentMode,_0x11e5c5[_0x3032b3(0x359)])&&_0x11e5c5[_0x3032b3(0x460)](currentMode,_0x3032b3(0x4a3)))return;const _0x46f915=document[_0x3032b3(0x3d2)](_0x3032b3(0x2aa)),_0x198b5c=_0x46f915[_0x3032b3(0x1da)](_0x11e5c5[_0x3032b3(0x32e)]),_0x5f401d=questionsData[currentQuestionIndex],_0x523342=_0x5f401d[_0x3032b3(0x4a9)];let _0x5ac714=_0x5f401d['choices'][_0x3032b3(0x468)](_0x1ac941=>_0x1ac941['id']===_0x523342);_0x46f915[_0x3032b3(0x316)]['add'](_0x11e5c5['VdaYC']),_0x198b5c[_0x3032b3(0x38c)]((_0x41a2f3,_0x337987)=>{const _0xf56073=_0x3032b3,_0x5d2db2={'jtWIE':_0xf56073(0x228),'AuhXI':_0x11e5c5[_0xf56073(0x39e)]};if(_0x11e5c5[_0xf56073(0x4b2)](_0x11e5c5[_0xf56073(0x43c)],_0x11e5c5[_0xf56073(0x2e5)]))_0x4c5cce(),_0x2dfccf[_0xf56073(0x3d2)](_0x5d2db2[_0xf56073(0x4cb)])[_0xf56073(0x46c)][_0xf56073(0x2b4)]=_0x5d2db2[_0xf56073(0x32c)];else{_0x41a2f3[_0xf56073(0x316)][_0xf56073(0x2cf)](_0x11e5c5[_0xf56073(0x34f)]);if(_0x337987===_0x5ac714)_0x41a2f3[_0xf56073(0x316)][_0xf56073(0x490)](_0x11e5c5['ZNrFj']);else{if(_0x11e5c5['bMWne'](_0x337987,selectedOption)&&!_0x2c3219)_0x41a2f3[_0xf56073(0x316)][_0xf56073(0x490)](_0x11e5c5['vhKwP']);}}}),_0x11e5c5[_0x3032b3(0x2b7)](showSolution);}function showSolution(){const _0x2755e3=_0x573d1a,_0x259bf6={'RZesn':'Previous\x20progress\x20cleared.','LMueB':'completed','GkDQQ':_0x2755e3(0x4a1),'Yzdzm':_0x2755e3(0x27d),'LXiec':function(_0x1e030d,_0x3c727d){return _0x1e030d!==_0x3c727d;},'qfMxP':_0x2755e3(0x4a3),'jnYEx':_0x2755e3(0x29f),'dTsYJ':'explanationVideoPlayer','SmpGR':function(_0x3e532d,_0x4a8462){return _0x3e532d===_0x4a8462;},'pzTEF':_0x2755e3(0x3cf),'YJuxj':_0x2755e3(0x43a),'UKHxX':function(_0x5727f1,_0x5bffa8,_0x3160ae){return _0x5727f1(_0x5bffa8,_0x3160ae);},'anzRw':_0x2755e3(0x2ce),'ljTbI':_0x2755e3(0x4d4),'QBwaQ':'solutionImages','bXcoy':_0x2755e3(0x277)};if(_0x259bf6[_0x2755e3(0x2c7)](currentMode,_0x2755e3(0x219))&&currentMode!==_0x259bf6[_0x2755e3(0x230)])return;const _0x1b17d2=questionsData[currentQuestionIndex];document[_0x2755e3(0x3d2)](_0x2755e3(0x49f))[_0x2755e3(0x324)]=_0x1b17d2[_0x2755e3(0x420)]||_0x259bf6[_0x2755e3(0x27a)];const _0x43fca8=document['getElementById']('solutionVideo'),_0x249132=document[_0x2755e3(0x3d2)](_0x259bf6[_0x2755e3(0x2e1)]),_0x403535=_0x1b17d2['explanation_video'];if(_0x403535){if(_0x259bf6[_0x2755e3(0x2ca)](_0x2755e3(0x3cf),_0x259bf6[_0x2755e3(0x268)])){_0x43fca8[_0x2755e3(0x316)][_0x2755e3(0x2cf)](_0x259bf6['YJuxj']);if(_0x403535[_0x2755e3(0x20d)](_0x2755e3(0x238)))_0x259bf6[_0x2755e3(0x48d)](setupVideo,_0x249132,_0x403535);else _0x249132[_0x2755e3(0x3ca)]=_0x403535;}else delete _0x2bd7c5[_0x57d446],_0x59749a[_0x2755e3(0x478)](_0x2755e3(0x447),_0x342bc7[_0x2755e3(0x43e)](_0x161b52)),_0x358a8c['log'](_0x259bf6[_0x2755e3(0x1e6)]);}else _0x43fca8[_0x2755e3(0x316)][_0x2755e3(0x490)](_0x259bf6[_0x2755e3(0x33b)]);const _0x570f32=document[_0x2755e3(0x3d2)](_0x259bf6['anzRw']);_0x570f32['innerHTML']='';_0x1b17d2['explanation_audio_eng']&&(_0x259bf6[_0x2755e3(0x309)]!==_0x259bf6[_0x2755e3(0x309)]?_0x54c58e[_0x2755e3(0x482)][_0x2755e3(0x38c)](_0x276bf4=>{const _0x2dc488=_0x2755e3;if(_0x276bf4)_0x225d8f[_0x2dc488(0x324)]+=_0x2dc488(0x357)+_0x276bf4+_0x2dc488(0x4b7);}):_0x570f32['innerHTML']+=_0x2755e3(0x22d)+_0x1b17d2['explanation_audio_eng']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>');_0x1b17d2[_0x2755e3(0x2d9)]&&(_0x570f32[_0x2755e3(0x324)]+=_0x2755e3(0x217)+_0x1b17d2[_0x2755e3(0x2d9)]+_0x2755e3(0x2ba));const _0xebdc64=document[_0x2755e3(0x3d2)](_0x259bf6['QBwaQ']);_0xebdc64['innerHTML']='',_0x1b17d2['explanation_images']&&_0x1b17d2[_0x2755e3(0x482)][_0x2755e3(0x38c)](_0x239581=>{const _0x164dbd=_0x2755e3,_0x58e399={'mocWb':_0x164dbd(0x447),'nmIiD':_0x259bf6['LMueB']};if(_0x259bf6[_0x164dbd(0x3df)]!==_0x259bf6[_0x164dbd(0x1eb)]){if(_0x239581)_0xebdc64[_0x164dbd(0x324)]+=_0x164dbd(0x357)+_0x239581+_0x164dbd(0x4b7);}else{const _0x3a1892=_0x345756[_0x164dbd(0x470)](_0x245558[_0x164dbd(0x1f5)](_0x58e399[_0x164dbd(0x210)]))||{},_0x584932=_0x446578[_0x164dbd(0x248)],_0x8b3d0=_0x232d09[_0x164dbd(0x283)]||0x0;_0x3a1892[_0x4c7f2c]={'score':_0x8b3d0,'total':_0x584932,'status':_0x58e399[_0x164dbd(0x4c1)],'completedOn':new _0x36f42b()[_0x164dbd(0x249)]()},_0x4e7360['setItem'](_0x58e399[_0x164dbd(0x210)],_0xfc04de[_0x164dbd(0x43e)](_0x3a1892));}}),document[_0x2755e3(0x3d2)](_0x259bf6[_0x2755e3(0x287)])[_0x2755e3(0x316)][_0x2755e3(0x2cf)](_0x259bf6[_0x2755e3(0x33b)]);}function submitQuiz(){const _0xd6dfdd=_0x573d1a,_0x32e0aa={'wqWWC':_0xd6dfdd(0x43a),'XWMkh':function(_0x4d1ccd,_0x2f9429,_0x44874b){return _0x4d1ccd(_0x2f9429,_0x44874b);},'ZtkBo':function(_0x2d41a3,_0x537377){return _0x2d41a3!==_0x537377;},'FzYxF':function(_0x486567,_0x3502e5){return _0x486567===_0x3502e5;},'TaAVt':function(_0x3fe601,_0x5aa7d3){return _0x3fe601===_0x5aa7d3;},'sUsLY':function(_0x346e3c,_0x4bcef5){return _0x346e3c===_0x4bcef5;},'aIyvC':_0xd6dfdd(0x435),'envqR':_0xd6dfdd(0x371),'OcoHR':_0xd6dfdd(0x452),'iYFhB':'incorrect','bnZoa':function(_0x9af400,_0xfbca7f){return _0x9af400(_0xfbca7f);},'xFZmS':function(_0x230220,_0x2696b2){return _0x230220-_0x2696b2;},'LDkZJ':'quizPerformanceData','jWSrl':function(_0x244189,_0x58431a){return _0x244189+_0x58431a;},'mBWfB':function(_0x35b737){return _0x35b737();}};if(timer)clearInterval(timer);if(!_0x32e0aa[_0xd6dfdd(0x345)](confirm,_0xd6dfdd(0x22c)))return;isQuizCompleted=!![];let _0x4538e4=0x0,_0xc3d2b8=0x0;const _0xb2e798=_0x32e0aa[_0xd6dfdd(0x395)](Date[_0xd6dfdd(0x30f)](),quizStartTime);questionsData[_0xd6dfdd(0x38c)]((_0x430aa9,_0x46b078)=>{const _0x193ddb=_0xd6dfdd,_0x5487df={'SeeNu':_0x32e0aa[_0x193ddb(0x26b)],'xFAaI':'.m3u8','LeiWm':function(_0x126852,_0xb3f624,_0x351117){const _0x19afd3=_0x193ddb;return _0x32e0aa[_0x19afd3(0x386)](_0x126852,_0xb3f624,_0x351117);}},_0x204b27=questionStates[_0x46b078];if(_0x32e0aa[_0x193ddb(0x34c)](_0x204b27['selectedAnswer'],null)){if(_0x32e0aa[_0x193ddb(0x4c2)]('jlxyX',_0x193ddb(0x1f8)))_0x472151();else{if(_0x32e0aa[_0x193ddb(0x350)](_0x430aa9[_0x193ddb(0x331)][_0x204b27['selectedAnswer']]['id'],_0x430aa9[_0x193ddb(0x4a9)])){if(_0x32e0aa[_0x193ddb(0x1ec)](_0x32e0aa['aIyvC'],_0x32e0aa[_0x193ddb(0x271)])){_0xd932c9[_0x193ddb(0x316)]['remove'](_0x5487df[_0x193ddb(0x1d5)]);if(_0x3d8a85[_0x193ddb(0x20d)](_0x5487df['xFAaI']))_0x5487df[_0x193ddb(0x3ea)](_0x583877,_0x4752ef,_0x29bab2);else _0x268fa8[_0x193ddb(0x3ca)]=_0x323851;}else _0x4538e4++,_0x204b27['status']=_0x32e0aa[_0x193ddb(0x3ed)];}else _0xc3d2b8++,_0x204b27['status']=_0x32e0aa[_0x193ddb(0x3f9)];}}});const _0x55fc76=JSON['parse'](localStorage[_0xd6dfdd(0x1f5)](_0x32e0aa[_0xd6dfdd(0x330)]))||[];_0x55fc76[_0xd6dfdd(0x1d3)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0xd6dfdd(0x30f)](),'totalTime':_0xb2e798,'stats':{'correct':_0x4538e4,'incorrect':_0xc3d2b8,'notAttempted':_0x32e0aa['xFZmS'](questionsData[_0xd6dfdd(0x248)],_0x32e0aa['jWSrl'](_0x4538e4,_0xc3d2b8))}}),localStorage[_0xd6dfdd(0x478)](_0xd6dfdd(0x379),JSON['stringify'](_0x55fc76)),stats[_0xd6dfdd(0x283)]=_0x4538e4,stats[_0xd6dfdd(0x258)]=_0xc3d2b8,_0x32e0aa[_0xd6dfdd(0x446)](markQuizAsCompleted),showPerformanceAnalysis(_0x4538e4,_0xc3d2b8,_0x32e0aa[_0xd6dfdd(0x395)](questionsData['length'],_0x4538e4+_0xc3d2b8),_0xb2e798);}function showPerformanceAnalysis(_0x3524db,_0x129941,_0x5c6141,_0x5ac8cc){const _0x4ea5c9=_0x573d1a,_0xfe1886={'jgvwC':function(_0x2d09b9,_0x19bec3){return _0x2d09b9>_0x19bec3;},'BepTx':function(_0x135aaa,_0x53f824){return _0x135aaa+_0x53f824;},'pEbEK':function(_0x14a62b,_0x3d9db7){return _0x14a62b*_0x3d9db7;},'xUdEe':function(_0x420aca,_0x4026ac){return _0x420aca/_0x4026ac;},'IizYd':'scoreCircle','xWOnJ':function(_0x1a962f,_0x26961c){return _0x1a962f*_0x26961c;},'VXdOG':'accuracyScore','DSgHd':_0x4ea5c9(0x2ae),'FyPyc':_0x4ea5c9(0x22a),'jJsip':'notAttemptedResult','uXeLL':function(_0x477b35,_0x52fa3b){return _0x477b35/_0x52fa3b;},'gkdIG':function(_0x93ddda,_0xc7be59){return _0x93ddda%_0xc7be59;},'xfVha':_0x4ea5c9(0x3ee),'hDdwU':function(_0xad2723,_0x2012e1){return _0xad2723/_0x2012e1;},'IbvIx':function(_0x2f251f,_0x466c80){return _0x2f251f/_0x466c80;},'lEDru':function(_0xa71a47,_0x17675c){return _0xa71a47/_0x17675c;},'bsTeT':_0x4ea5c9(0x213),'clIGH':_0x4ea5c9(0x43a)},_0x117182=document['getElementById'](_0x4ea5c9(0x34b)),_0x47f4a7=_0xfe1886[_0x4ea5c9(0x2fc)](_0xfe1886[_0x4ea5c9(0x25b)](_0x3524db,_0x129941),0x0)?Math[_0x4ea5c9(0x455)](_0xfe1886[_0x4ea5c9(0x246)](_0xfe1886[_0x4ea5c9(0x24d)](_0x3524db,_0x3524db+_0x129941),0x64)):0x0,_0x3b5173=0x2*Math['PI']*0x41,_0x423461=document[_0x4ea5c9(0x3d2)](_0xfe1886[_0x4ea5c9(0x413)]);_0x423461[_0x4ea5c9(0x46c)]['strokeDasharray']=_0x3b5173+'\x20'+_0x3b5173,_0x423461[_0x4ea5c9(0x46c)][_0x4ea5c9(0x26d)]=_0x3b5173-_0xfe1886['xWOnJ'](_0xfe1886[_0x4ea5c9(0x24d)](_0x47f4a7,0x64),_0x3b5173),document[_0x4ea5c9(0x3d2)](_0xfe1886[_0x4ea5c9(0x2d2)])['textContent']=_0x47f4a7+'%',document[_0x4ea5c9(0x3d2)](_0xfe1886[_0x4ea5c9(0x388)])[_0x4ea5c9(0x235)]=questionsData['length'],document[_0x4ea5c9(0x3d2)](_0xfe1886[_0x4ea5c9(0x2d4)])[_0x4ea5c9(0x235)]=_0x3524db,document[_0x4ea5c9(0x3d2)](_0x4ea5c9(0x3f2))[_0x4ea5c9(0x235)]=_0x129941,document['getElementById'](_0xfe1886['jJsip'])['textContent']=_0x5c6141;const _0x5c7cf9=Math[_0x4ea5c9(0x445)](_0xfe1886['xUdEe'](_0x5ac8cc,0xea60)),_0x38fb37=Math[_0x4ea5c9(0x445)](_0xfe1886[_0x4ea5c9(0x3b7)](_0xfe1886[_0x4ea5c9(0x28e)](_0x5ac8cc,0xea60),0x3e8));document[_0x4ea5c9(0x3d2)](_0xfe1886['xfVha'])[_0x4ea5c9(0x235)]=_0x5c7cf9+':'+_0x38fb37[_0x4ea5c9(0x2fd)]()[_0x4ea5c9(0x2bb)](0x2,'0');const _0x423a1e=_0xfe1886[_0x4ea5c9(0x39b)](_0x5ac8cc,questionsData[_0x4ea5c9(0x248)]),_0x157f18=Math[_0x4ea5c9(0x445)](_0xfe1886[_0x4ea5c9(0x3e6)](_0x423a1e,0xea60)),_0x4a130d=Math[_0x4ea5c9(0x445)](_0xfe1886['lEDru'](_0xfe1886[_0x4ea5c9(0x28e)](_0x423a1e,0xea60),0x3e8));document[_0x4ea5c9(0x3d2)](_0xfe1886[_0x4ea5c9(0x206)])[_0x4ea5c9(0x235)]=_0x157f18+':'+_0x4a130d[_0x4ea5c9(0x2fd)]()[_0x4ea5c9(0x2bb)](0x2,'0'),_0x117182['classList']['remove'](_0xfe1886[_0x4ea5c9(0x408)]);}function closePerformanceModal(){const _0xf2e4d8=_0x573d1a;document[_0xf2e4d8(0x3d2)]('performanceModal')['classList']['add'](_0xf2e4d8(0x43a));}function reviewQuestions(){const _0x1bc11f=_0x573d1a,_0x10f2ad={'qMuGN':function(_0x40e485,_0x6c068c){return _0x40e485===_0x6c068c;},'YdVYs':_0x1bc11f(0x2db),'OYTum':function(_0x4d9754,_0x2eccc8){return _0x4d9754!==_0x2eccc8;},'uBNfG':function(_0x5eb7c5,_0x35f04b){return _0x5eb7c5===_0x35f04b;},'JOEbA':_0x1bc11f(0x452),'Ckteq':_0x1bc11f(0x200),'yrxKC':'incorrect','kxmXP':'Incorrect','iKINO':_0x1bc11f(0x3b0),'TkFYd':function(_0x5b5a52,_0x15a25f){return _0x5b5a52+_0x15a25f;},'KCnwF':'green','xDRha':_0x1bc11f(0x348),'onOMB':_0x1bc11f(0x40f),'LMUPp':_0x1bc11f(0x341),'raopI':_0x1bc11f(0x37a),'PSgSK':_0x1bc11f(0x43a),'TAzuY':_0x1bc11f(0x3d9)};document[_0x1bc11f(0x3d2)](_0x10f2ad[_0x1bc11f(0x296)])[_0x1bc11f(0x316)][_0x1bc11f(0x2cf)](_0x10f2ad[_0x1bc11f(0x270)]);const _0x4e8413=document[_0x1bc11f(0x3d2)](_0x10f2ad[_0x1bc11f(0x260)]);_0x4e8413['innerHTML']='',questionsData[_0x1bc11f(0x38c)]((_0x4404b9,_0x75b96e)=>{const _0x9f8dc3=_0x1bc11f,_0x20b9e9={'fVzfA':function(_0x561846,_0x247f0a){return _0x561846===_0x247f0a;},'NjUOp':function(_0xf37d21,_0x27c3b9){return _0x10f2ad['qMuGN'](_0xf37d21,_0x27c3b9);},'SCDgX':_0x9f8dc3(0x2f1)},_0x129831=questionStates[_0x75b96e],_0x15d4ec=_0x4404b9[_0x9f8dc3(0x4a9)];let _0x518b5c=_0x10f2ad[_0x9f8dc3(0x1db)],_0x2574a6=_0x9f8dc3(0x4c7);if(_0x10f2ad['OYTum'](_0x129831[_0x9f8dc3(0x201)],null)){const _0x44f817=_0x4404b9[_0x9f8dc3(0x331)][_0x129831['selectedAnswer']];_0x10f2ad[_0x9f8dc3(0x42d)](_0x44f817['id'],_0x15d4ec)?(_0x518b5c=_0x10f2ad[_0x9f8dc3(0x476)],_0x2574a6=_0x10f2ad[_0x9f8dc3(0x2b1)]):(_0x518b5c=_0x10f2ad['yrxKC'],_0x2574a6=_0x10f2ad['kxmXP']);}const _0x917410=document['createElement'](_0x10f2ad[_0x9f8dc3(0x295)]);_0x917410['className']=_0x9f8dc3(0x3db)+_0x518b5c;let _0x416c11=(_0x4404b9[_0x9f8dc3(0x331)]||[])[_0x9f8dc3(0x49d)]((_0x627fb7,_0x4f3f51)=>{const _0x1540d0=_0x9f8dc3,_0x2dd665=_0x20b9e9[_0x1540d0(0x355)](_0x129831[_0x1540d0(0x201)],_0x4f3f51),_0x53ff9a=_0x20b9e9['NjUOp'](_0x627fb7['id'],_0x15d4ec);let _0x895cd=_0x1540d0(0x2df);if(_0x53ff9a)_0x895cd=_0x20b9e9[_0x1540d0(0x1d7)];else{if(_0x2dd665)_0x895cd=_0x1540d0(0x1ef);}return _0x1540d0(0x499)+_0x895cd+_0x1540d0(0x362)+String[_0x1540d0(0x2e6)](0x41+_0x4f3f51)+_0x1540d0(0x46d)+_0x627fb7[_0x1540d0(0x2c3)]+_0x1540d0(0x21d);})[_0x9f8dc3(0x24c)]('');const _0x41a9ea=_0x4404b9[_0x9f8dc3(0x453)]?_0x9f8dc3(0x4ca)+_0x75b96e+'\x22\x20data-src=\x22'+_0x4404b9['explanation_video']+_0x9f8dc3(0x318):'';let _0xfee144='';if(_0x4404b9['explanation_audio_eng'])_0xfee144+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22'+_0x4404b9[_0x9f8dc3(0x37e)]+_0x9f8dc3(0x2ba);if(_0x4404b9[_0x9f8dc3(0x2d9)])_0xfee144+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22'+_0x4404b9[_0x9f8dc3(0x2d9)]+_0x9f8dc3(0x2ba);let _0x4aed5e=(_0x4404b9['explanation_images']||[])['map'](_0x49fdc0=>_0x49fdc0?_0x9f8dc3(0x357)+_0x49fdc0+_0x9f8dc3(0x4b7):'')['join']('');_0x917410[_0x9f8dc3(0x324)]='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20'+_0x10f2ad['TkFYd'](_0x75b96e,0x1)+_0x9f8dc3(0x215)+(_0x10f2ad[_0x9f8dc3(0x4d3)](_0x518b5c,_0x10f2ad[_0x9f8dc3(0x476)])?_0x10f2ad[_0x9f8dc3(0x226)]:_0x10f2ad[_0x9f8dc3(0x42d)](_0x518b5c,_0x10f2ad[_0x9f8dc3(0x4bc)])?_0x10f2ad[_0x9f8dc3(0x3b8)]:_0x10f2ad[_0x9f8dc3(0x41c)])+_0x9f8dc3(0x3bb)+_0x2574a6+_0x9f8dc3(0x3ae)+_0x4404b9['text']+_0x9f8dc3(0x33e)+_0x416c11+_0x9f8dc3(0x4b1)+(_0x4404b9[_0x9f8dc3(0x420)]||_0x10f2ad[_0x9f8dc3(0x2a0)])+_0x9f8dc3(0x218)+_0x41a9ea+_0x9f8dc3(0x3c0)+_0xfee144+_0x9f8dc3(0x3c0)+_0x4aed5e+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>',_0x4e8413[_0x9f8dc3(0x207)](_0x917410);}),initializeReviewVideos();}function initializeReviewVideos(){const _0x49abdf=_0x573d1a,_0x218455={'MKdHw':function(_0x16fc4e,_0x324fae){return _0x16fc4e===_0x324fae;},'UIVTf':_0x49abdf(0x458),'NRXnt':_0x49abdf(0x452),'cQayW':_0x49abdf(0x300),'vhqDS':function(_0x3548af){return _0x3548af();},'SDxGV':function(_0xe839f7,_0x55654e){return _0xe839f7(_0x55654e);},'Teqox':'MBsBf','DOYsw':'.m3u8','Dayok':_0x49abdf(0x3d1),'AhzxC':'MWHaB','uEmPl':function(_0xb32aab,_0x332431,_0x16e695){return _0xb32aab(_0x332431,_0x16e695);}};document[_0x49abdf(0x1da)](_0x49abdf(0x2f8))[_0x49abdf(0x38c)](_0x1c82a9=>{const _0x4436a0=_0x49abdf,_0x138215={'onsxu':function(_0x5d872b,_0x179740){const _0x1960e4=_0x2a41;return _0x218455[_0x1960e4(0x3d8)](_0x5d872b,_0x179740);},'TacwF':_0x218455[_0x4436a0(0x414)],'wlrFD':_0x218455[_0x4436a0(0x39d)],'iBIUZ':_0x218455[_0x4436a0(0x3e5)],'uyALY':function(_0x5b1f28){const _0x261e0c=_0x4436a0;return _0x218455[_0x261e0c(0x29c)](_0x5b1f28);},'abxdp':function(_0x25b2d0,_0x282a83){const _0x417973=_0x4436a0;return _0x218455[_0x417973(0x3cb)](_0x25b2d0,_0x282a83);}};if('faqEF'===_0x218455['Teqox'])_0x4be72d[_0x4436a0(0x3d2)]('quizSidebar')[_0x4436a0(0x316)]['toggle'](_0x4436a0(0x4ad));else{const _0x1da4fe=_0x1c82a9[_0x4436a0(0x229)][_0x4436a0(0x3ca)];if(_0x1da4fe&&_0x1da4fe[_0x4436a0(0x20d)](_0x218455[_0x4436a0(0x37b)])){if(_0x218455[_0x4436a0(0x410)]===_0x218455[_0x4436a0(0x1f2)]){const _0x41c3bc=_0x327d9f[_0x41d172],_0x2ea874=_0x41c3bc[_0x4436a0(0x4a9)];if(_0x32ba6e===null)return;const _0x4cc23f=_0x41c3bc[_0x4436a0(0x331)][_0x4d604e],_0x3a517d=_0x138215['onsxu'](_0x4cc23f['id'],_0x2ea874);if(_0x138215[_0x4436a0(0x44f)](_0x21dd06[_0x296f52]['status'],_0x138215[_0x4436a0(0x3f6)])){_0x5f09ac[_0x4436a0(0x42e)]++,_0x239631['notAttempted']--;if(_0x3a517d)_0xf6df36[_0x4436a0(0x283)]++;else _0x5bf2eb[_0x4436a0(0x258)]++;}_0xacae99[_0x4e636b][_0x4436a0(0x477)]=_0x3a517d?_0x138215[_0x4436a0(0x4af)]:_0x138215['iBIUZ'],_0x138215[_0x4436a0(0x234)](_0x409d86),_0x138215['abxdp'](_0x528fca,_0x3a517d),_0x138215[_0x4436a0(0x234)](_0x50b2ca);}else _0x218455[_0x4436a0(0x433)](setupVideo,_0x1c82a9,_0x1da4fe);}else _0x1da4fe&&(_0x1c82a9[_0x4436a0(0x3ca)]=_0x1da4fe);}});}function _0x50fb(){const _0x5496f1=['TDIhR','VkHou','nav-btn-correct','uBNfG','totalAttempted','canPlayType','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','questionText','OBHhP','uEmPl','<p>The\x20given\x20scenario\x20and\x20the\x20peripheral\x20smear\x20findings\x20(increased\x20WBCs\x20with\x20myelocytes,\x20metamyelocytes,\x20and\x20band\x20forms),\x20is\x20suggestive\x20of\x20chronic\x20myelogenous\x20leukemia\x20(<strong>CML</strong>).&nbsp;<strong>Bosutinib</strong>&nbsp;is\x20approved\x20for\x20use\x20in\x20this\x20condition<strong>&nbsp;</strong>only\x20for<strong>\x20resistant\x20and/or\x20intolerant\x20</strong>cases\x20and\x20not\x20in\x20newly\x20diagnosed\x20cases.</p>\x0a<p>Agents\x20that\x20can\x20be\x20used\x20as\x20first-line\x20for\x20CML\x20are:</p>\x0a<ul>\x0a<li>Imatinib</li>\x0a<li>Dasatinib</li>\x0a<li>Nilotinib&nbsp;</li>\x0a</ul>\x0a<p>Dasatinib\x20and\x20nilotinib\x20can\x20be\x20used\x20in\x20newly\x20diagnosed\x20cases\x20of\x20CML,\x20that\x20are\x20found\x20to\x20be\x20imatinib-resistant.</p>','asJAj','cSOjN','Panitumumab','Dual\x20inhibitor\x20of\x20EGFR\x20and\x20HER\x202\x20tyrosine\x20kinase','VUGiM','hidden','zeCiA','YjsbX','zQzwQ','stringify','Fusion\x20protein\x20of\x20IL-2\x20and\x20pertussis\x20toxin','A\x20patient\x20with\x20uncontrolled\x20diabetes\x20is\x20diagnosed\x20to\x20have\x20diabetic\x20macular\x20edema.\x20Which\x20of\x20the\x20following\x20anti-VEGF\x20therapies\x20is\x20effective\x20in\x20the\x20treatment\x20of\x20this\x20condition?','QYXaJ','Denosumab','nav-btn-bookmarked','sRWOF','floor','mBWfB','userHistory','Which\x20of\x20the\x20following\x20is\x20a\x20third\x20generation\x20BCR-ABL\x20kinase\x20inhibitor?','tgayn','ZtDWr','Adriamycin','width','YMlwK','fMCRu','onsxu','filter','Clomiphene\x20citrate','correct','explanation_video','HER2\x20receptors','round','KLzmO','A\x20patient\x20undergoing\x20adjuvant\x20radiotherapy\x20for\x20an\x20oral\x20malignancy\x20is\x20prescribed\x20a\x20radioprotective\x20drug.\x20Identify\x20this\x20drug.','not_attempted','QQDfq','UPlJa','navBtn_','completed','kYLDX','boHqw','eXXRB','ZMHob','Which\x20of\x20the\x20following\x20conditions\x20is\x20apalutamide\x20approved\x20for?','rlOto','What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20imatinib\x20mesylate?','MfAgB','caIMV','SIMwe','Paclitaxel','findIndex','vRiAq','No\x20question\x20text\x20available','TRbgr','style','</span><span>','Ramucirumab','customQuizData','parse','No\x20questions\x20available\x20for\x20this\x20quiz.','disabled','ioKTE','zGVba','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','JOEbA','status','setItem','EHDbi','aXKzD','5980GxaoYL','rsZbP','uNwUW','timeDisplay','weQdP','incorrectCount','IfJHG','explanation_images','Dabrafenib','MXwHP','bookmarked','kOWmD','GuVZf','JXUJj','vALUn','rupSP','suGng','cvvEa','UKHxX','resume','SqYAn','add','Prostatic\x20acid\x20phosphatase','MYUdx','bookmarkText','Use\x20of\x20lenalidomide\x20over\x20thalidomide\x20would\x20lead\x20to\x20the\x20reduction\x20of\x20incidence\x20of\x20the\x20following\x20side\x20effects,\x20except\x20___________.','aRvvh','Cobimetinib','nav-btn-current','NZUJz','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','tPwno','studyModeLegend','nGeNy','map','rebes','solutionText','QeXUl','MvEBc','split','timed_study','lwzML','Riociguat','Bookmark','CjGJI','questionStates','correct_choice_id','kuQCR','<p><strong>Erlotinib</strong>\x20is\x20an\x20epidermal\x20growth\x20factor\x20receptor\x20(<strong>EGFR</strong>)\x20<strong>inhibitor.</strong></p>\x0a<p>Classification\x20of&nbsp;<strong>BCR-ABL\x20kinase\x20inhibitors</strong>:&nbsp;</p>\x0a<ul>\x0a<li><strong>First-generation</strong>:<strong>&nbsp;</strong>most\x20likely\x20to\x20develop\x20resistance.\x0a<ul>\x0a<li>Imatinib&nbsp;</li>\x0a</ul>\x0a</li>\x0a<li><strong>Second\x20generation</strong>:\x20active\x20against\x20imatinib-resistant\x20CML\x20cases\x20but\x20not\x20against\x20T315I\x20mutant\x20cases.&nbsp;\x0a<ul>\x0a<li>Nilotinib</li>\x0a<li>Dasatinib&nbsp;</li>\x0a<li>Bosutinib&nbsp;</li>\x0a</ul>\x0a</li>\x0a<li><strong>Third\x20generation</strong>:\x20active\x20against&nbsp;T315I\x20mutant\x20CML\x20cases\x20and\x20other\x20known\x20mutant\x20cases.&nbsp;\x0a<ul>\x0a<li>Ponatinib</li>\x0a</ul>\x0a</li>\x0a</ul>','XzLhl','open','Atopic\x20eczema','wlrFD','apply','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','bMWne','VQUwe','Thalidomide','constructor','6779509LTQgCs','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','questionNav','Which\x20of\x20the\x20following\x20is\x20not\x20a\x20BCR-ABL\x20tyrosine\x20kinase\x20inhibitor?','PoJNR','pathname','yrxKC','5|0|3|2|1|4','psNro','XdIph','Blocks\x20the\x20action\x20of\x20chimeric\x20fusion\x20protein\x20of\x20BCR-ABL','nmIiD','FzYxF','ttKNY','tmDqy','JOFTx','Dasatinib','Not\x20Attempted','name','fMNOn','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','jtWIE','xbLCg','deVnd','Rosacea','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','dPaoG','\x20-\x20Brain\x20And\x20Scalpel','<p><strong>Amifostine</strong>&nbsp;is\x20the\x20<strong>radioprotective</strong>\x20drug\x20that\x20has\x20been\x20prescribed\x20to\x20this\x20patient.</p>\x0a<p>It\x20is\x20an\x20organic\x20thiophosphate\x20cytoprotective\x20agent\x20that\x20is\x20<strong>indicated</strong>\x20for\x20the\x20following\x20conditions:</p>\x0a<ul>\x0a<li>Reduction\x20of\x20<strong>nephrotoxicity</strong>\x20associated\x20with\x20<strong>cisplatin.</strong></li>\x0a<li>Reduction\x20of\x20<strong>xerostomia</strong>\x20in\x20patients\x20with\x20<strong>head</strong>\x20and\x20<strong>neck\x20cancer</strong>\x20undergoing\x20postoperative\x20irradiation.</li>\x0a</ul>','qMuGN','YEOuo','SwSQY','ZWJCo','Monoclonal\x20antibody\x20against\x20CD30','Vascular\x20endothelial\x20growth\x20factor','push','VRUOj','SeeNu','Erythema\x20nodosum\x20leprosum','SCDgX','ASzTk','eKllO','querySelectorAll','YdVYs','questions','BowBg','Increased\x20efflux','PhZfP','heTqL','IySwi','2843724SstAEK','Nilotinib','Ipilimumab','Lokpj','RZesn','prototype','Zlfrw','oZHbf','Sunitinib','Yzdzm','sUsLY','mAKvx','FVxIG','border-red-500','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','Sorafenib','AhzxC','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','Olaparib','getItem','Non-competitive\x20inhibition\x20of\x20ATP\x20binding\x20site','SeaaQ','paRDG','<p><strong>Imatinib</strong>\x20mesylate\x20<strong>blocks</strong>\x20the\x20action\x20of\x20the&nbsp;<strong>chimeric</strong>\x20<strong>fusion\x20protein</strong>\x20of\x20BCR-ABL.\x20It\x20targets\x20the\x20<strong>BCR-ABL\x20tyrosine\x20kinase</strong>\x20and\x20inhibits\x20the\x20activity\x20of\x20the\x20fusion\x20protein.</p>\x0a<p>A\x20single\x20molecular\x20event,\x20<strong>9:22\x20translocation</strong>,\x20leads\x20to\x20the\x20expression\x20of\x20the\x20Abelson\x20proto-oncogene\x20kinase\x20(ABL)\x20fused\x20to\x20BCR\x20(breakpoint\x20cluster\x20region)\x20yielding\x20a\x20constitutively\x20activated\x20protein\x20kinase\x20in\x20chronic\x20myelogenous\x20leukemia.&nbsp;Imatinib\x20causes\x20remission\x20in\x20&gt;90%\x20of\x20patients\x20in\x20the\x20chronic\x20phase\x20of\x20CML.</p>','Point\x20mutations\x20in\x20kinase\x20domain','HncLE','https://dhmbxeygs57ff.cloudfront.net/uploads/5e5de2d60b9f4b5cb196af855a64327fx1280x1399.JPEG','tNMcr','elAGK','NWehb','Correct','selectedAnswer','tfBDJ','yWTtE','IaNtf','bmCqh','bsTeT','appendChild','RxOPL','currentQuestionIndex','WtSFY','OWQsy','nAllp','includes','BntTk','159676IyEdNr','mocWb','eBfTI','RHOhB','avgTimeResult','545mItjhf','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','CAOPl','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','study','ikcSk','keydown','A\x20patient\x20is\x20referred\x20to\x20your\x20center\x20for\x20the\x20management\x20of\x20hepatocellular\x20carcinoma.\x20Imaging\x20reveals\x20a\x20large\x20lesion\x20in\x20the\x20liver\x20with\x20multiple\x20intrahepatic\x20metastases.\x20The\x20tumor\x20is\x20found\x20to\x20be\x20unresectable.\x20Which\x20of\x20the\x20following\x20is\x20considered\x20as\x20first-line\x20treatment\x20for\x20this\x20patient?','</span></div>','isSupported','click','key','.option-button','mYDtz','contains','Progress\x20loaded.','className','KCnwF','Regorafenib','modeModal','dataset','correctResult','LvJIr','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','fnEYQ','testModeLegend','qfMxP','FXeXF','FQVXp','Tmcqw','uyALY','textContent','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','HGkHh','.m3u8','timerContainer','bind','OeTqS','TeIoB','AZhZw','aiCyw','Cisplatin','ynZoO','eJJVf','OaGPa','wVmZI','title','selected','pEbEK','Vismodegib','length','toISOString','Evaluation\x20of\x20a\x20patient\x20with\x20CLL\x20\x20showed\x20evidence\x20of\x2017p\x20deletion.\x20Which\x20of\x20the\x20following\x20is\x20a\x20BCL-2\x20inhibitor\x20approved\x20for\x20use\x20in\x20this\x20condition?','wnSbZ','join','xUdEe','Which\x20of\x20the\x20following\x20is\x20a\x20proteasome\x20inhibitor?','\x22\x20data-option-index=\x22','get','bVZNF','Irinotecan','A\x20patient\x20with\x20trastuzumab-refractory\x20breast\x20cancer\x20is\x20started\x20on\x20lapatinib.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20regarding\x20this\x20drug?','bIoIs','Which\x20of\x20the\x20following\x20inhibits\x20\x20V600E\x20mutated\x20BRAF?','Erlotinib','<div\x20class=\x22ng-scope\x22>\x0a<div\x20class=\x22ng-scope\x22>\x0a<p>The\x20scenario\x20is\x20suggestive\x20of\x20<strong>metastatic\x20melanoma</strong>\x20and<strong>\x20trametinib</strong>\x20is\x20used\x20in\x20this\x20condition.\x20It\x20is\x20a\x20<strong>reversible\x20inhibitor</strong>\x20of\x20the\x20mitogen-activated\x20extracellular\x20signal-regulated\x20kinase\x20(<strong>MEK</strong>).\x20It\x20inhibits\x20the\x20serine-threonine\x20kinase\x20domain\x20of\x20BRAF\x20V600E\x20mutant\x20of\x20MEK.</p>\x0a<p>It\x20can\x20be\x20used\x20as\x20a\x20<strong>single\x20agent</strong>\x20but\x20it\x20is\x20more\x20effective\x20when\x20used\x20with\x20BRAF\x20inhibitors\x20like\x20dabrafenib.</p>\x0a<p><strong>Adverse\x20effects</strong>\x20of\x20this\x20drug\x20include:&nbsp;</p>\x0a<ul>\x0a<li>Cutaneous\x20rash</li>\x0a<li>Acneiform\x20dermatitis</li>\x0a<li>Diarrhea</li>\x0a<li>Fatigue</li>\x0a<li>Nausea</li>\x0a<li>Lymphedema.</li>\x0a<li>Cardiomyopathy</li>\x0a<li>Hypertension</li>\x0a<li>Hemorrhage</li>\x0a<li>Interstitial\x20lung\x20disease</li>\x0a<li>Ocular\x20toxic\x20effects.</li>\x0a</ul>\x0a<p>Options\x20A\x20and\x20B:\x20Dabrafenib\x20and\x20vemurafenib\x20are\x20BRAF\x20inhibitors\x20used\x20in\x20metastatic\x20melanoma.</p>\x0a<p>Option\x20D:\x20Ipilimumab\x20is\x20a\x20human\x20cytotoxic\x20T-lymphocyte\x20antigen\x204\x20(CTLA-4)\x20blocking\x20antibody\x20used\x20in\x20metastatic\x20or\x20unresectable\x20melanoma.</p>\x0a</div>\x0a</div>','incorrectAnswers','LxPQv','Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20for\x20the\x20treatment\x20of\x20a\x20patient\x20with\x20hormone-responsive\x20breast\x20cancer?','BepTx','DWsIM','gmCMa','ojKge','QPkND','TAzuY','WLbtz','attachMedia','ivaHO','zvhzk','<p><strong>Afatinib</strong>\x20binds\x20covalently\x20with\x20epidermal\x20growth\x20factor\x20receptor\x20tyrosine\x20kinase\x20(<strong>EGFR-TK</strong>)\x20also\x20known\x20as\x20Her-1\x20receptor\x20and\x20<strong>inhibits</strong>\x20it\x20<strong>irreversibly</strong>.&nbsp;It\x20is\x20approved\x20for\x20the\x20use\x20of\x20<strong>metastatic\x20non-small\x20cell\x20lung\x20cancer.</strong></p>\x0a<p>Gefitinib\x20and\x20erlotinib\x20compete\x20with\x20ATP\x20binding\x20to\x20EGFR\x20and\x20results\x20in\x20competitive\x20inhibition,\x20which\x20is\x20reversible.</p>','2|5|3|1|0|4','Palbociclib','pzTEF','replace','gksin','wqWWC','fjuAg','strokeDashoffset','mJvLX','EyTwq','PSgSK','envqR','Gemcitabine','HBNZY','Njgqr','Which\x20among\x20the\x20following\x20is\x20an\x20irreversible\x20inhibitor\x20of\x20EGFR\x20tyrosine\x20kinase?','mrHJk','solutionContainer','{}.constructor(\x22return\x20this\x22)(\x20)','Dual\x20inhibitor\x20of\x20VEGFR\x20and\x20MET\x20tyrosine\x20kinase','jnYEx','question_video','Previous\x20progress\x20cleared.','Ezxgk','ljfho','LzrsK','SHCOa','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Cetuximab','correctAnswers','Ponatinib','OUiqg','console','bXcoy','GqBIO','sAphA','XlKEh','Venetoclax','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','A\x2067-year-old\x20man\x20presented\x20with\x20fatigue\x20and\x20weight\x20loss.\x20On\x20examination,\x20pallor\x20and\x20splenomegaly\x20were\x20noted.\x20Peripheral\x20blood\x20smear\x20examination\x20findings\x20are\x20shown\x20in\x20the\x20image.\x20Which\x20of\x20the\x20following\x20BCR-ABL\x20tyrosine\x20kinase\x20inhibitors\x20is\x20not\x20a\x20first-line\x20agent\x20for\x20this\x20condition?','gkdIG','BOqpl','HfNmO','CMbVH','Bookmarked','jucCB','HIV-associated\x20peripheral\x20neuropathy','iKINO','raopI','answered','<p\x20style=\x22text-align:\x20left;\x22>A\x20<strong>topical</strong>\x20solution\x20of<strong>&nbsp;hydrogen\x20peroxide</strong>&nbsp;has\x20been\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>raised\x20seborrheic\x20keratoses</strong>.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Hydrogen\x20peroxide\x20is\x20a\x20<strong>keratolytic\x20agent</strong>.\x20Its\x20exact\x20mechanism\x20of\x20action\x20in\x20the\x20treatment\x20of\x20seborrheic\x20keratoses<strong>&nbsp;</strong>is\x20not\x20fully\x20understood.\x20Supraphysiologic\x20concentrations\x20may\x20cause\x20oxidative\x20damage\x20and\x20death\x20to\x20seborrheic\x20keratosis\x20cells.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Hydrogen\x20peroxide\x20is\x20commonly\x20used\x20as\x20a\x20<strong>disinfectant</strong>\x20to\x20<strong>clean\x20wounds</strong>.\x20It\x20can\x20also\x20be\x20used\x20as\x20a\x20<strong>mouthwash</strong>.&nbsp;</p>','JyqRB','udjeW','wwgyj','vhqDS','Marrow','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','No\x20solution\x20provided','LMUPp','endsWith','fvemo','A\x20patient\x20undergoing\x20treatment\x20for\x20colon\x20cancer\x20develops\x20hypertension.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20most\x20commonly\x20implicated?','vsxeb','rpHHP','Bone\x20marrow\x20suppression','preventDefault','pop','vMDcW','optionsContainer','Vascular\x20endothelial\x20growth\x20factor\x20receptor','SbOIW','rTXfM','totalQuestionsResult','aVkbM','bookmarkedQuestions','Ckteq','23468NfeQjg','KAZSX','display','tZeGb','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','DGgtX','kWbwL','<p><strong>Lapatinib&nbsp;</strong>is\x20a\x20<strong>dual\x20inhibitor</strong>\x20of\x20epidermal\x20growth\x20factor\x20(<strong>EGFR</strong>)\x20and\x20human\x20epidermal\x20growth\x20factor\x202\x20(<strong>HER2</strong>)\x20<strong>tyrosine\x20kinase</strong>.</p>\x0a<p>Lapatinib\x20in\x20combination\x20with\x20capecitabine\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20metastatic\x20HER2-positive\x20and\x20trastuzumab-refractory\x20<strong>breast\x20cancer.</strong></p>','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','padStart','statsBar','hierarchy','271356hhlXVU','removeItem','Mark\x20for\x20Review','wUOoD','GquqE','text','ZdUHj','Monoclonal\x20antibody\x20against\x20CD33','cidPE','LXiec','yJtIF','Fusion\x20protein\x20of\x20IL-2\x20and\x20diptheria\x20toxin','SmpGR','createElement','QrHzY','Ranibuzumab','solutionAudio','remove','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','VsCMc','VXdOG','Psoriasis','FyPyc','warn','sxuwm','location','<p>The\x20given\x20scenario\x20is\x20suggestive\x20of\x20the\x20<strong>development</strong>\x20of\x20<strong>resistance</strong>\x20to\x20<strong>imatinib,</strong>\x20which\x20is\x20a\x20<strong>tyrosine\x20kinase\x20inhibitor</strong>.\x20This\x20condition\x20arises\x20due\x20to\x20<strong>point\x20mutations</strong>\x20in\x20three\x20separate\x20regions\x20of\x20the\x20<strong>kinase\x20domain</strong>.</p>\x0a<p>The\x20contact\x20points\x20between\x20imatinib\x20and\x20the\x20enzyme\x20become\x20sites\x20of\x20mutations\x20in\x20drug-resistant\x20leukemic\x20cells\x20and\x20hence\x20these\x20<strong>mutations\x20prevent\x20tight\x20binding</strong>\x20of\x20the\x20<strong>drug</strong>\x20and\x20lock\x20the\x20enzyme\x20in\x20its\x20open\x20configuration\x20(the\x20configuration\x20in\x20which\x20it\x20has\x20access\x20to\x20the\x20substrate\x20and\x20is\x20enzymatically\x20active).</p>\x0a<p>Mechanisms\x20other\x20than\x20BCR-ABL\x20kinase\x20mutations\x20play\x20a\x20minor\x20role\x20in\x20resistance\x20to\x20imatinib.\x20They\x20include:</p>\x0a<ul>\x0a<li>Amplification\x20of\x20the\x20wild-type\x20kinase\x20gene\x20has\x20been\x20identified\x20in\x20some\x20cases.</li>\x0a<li>Overexpression\x20of\x20MDR-gene\x20leading\x20to\x20increased\x20drug\x20efflux\x20transporter\x20has\x20been\x20shown\x20experimentally\x20but\x20not\x20implicated\x20in\x20clinical\x20resistance.</li>\x0a</ul>\x0a<p>Nilotinib\x20retains\x20inhibitory\x20activity\x20in\x20the\x20presence\x20of\x20most\x20point\x20mutations\x20that\x20confer\x20resistance\x20to\x20imatinib.</p>','explanation_audio_hin','A\x2063-year-old\x20postmenopausal\x20woman\x20came\x20to\x20the\x20OPD\x20with\x20a\x2012\x20cm\x20adnexal\x20mass.\x20Her\x20CA-125\x20levels\x20were\x20raised\x20and\x20her\x20risk\x20of\x20malignancy\x20index\x20was\x20calculated\x20to\x20be\x20250.\x20PET\x20scan\x20revealed\x20hepatic\x20metastases.\x20Which\x20PARP\x20inhibitor\x20can\x20you\x20use\x20in\x20her\x20treatment?','not-attempted','ykieF','toggle','xeKmp','border-gray-600','ewMqU','dTsYJ','rxqdm','boGxb','Vemurafenib','BQmay','fromCharCode','dyrtZ','Which\x20among\x20the\x20following\x20is\x20a\x20hedgehog\x20pathway\x20inhibitor?','__proto__','GjZBn','A\x2060-year-old\x20woman\x20was\x20diagnosed\x20with\x20melanoma.\x20Sentinel\x20lymph\x20node\x20biopsy\x20showed\x20malignant\x20cells.\x20\x20Which\x20among\x20the\x20following\x20is\x20a\x20recombinant\x20interleukin-2\x20preparation\x20approved\x20for\x20use\x20in\x20this\x20condition?','ZmLVt','juXiz','HIV-associated\x20aphthous\x20ulcers','JiXYj','markReviewBtn','border-green-500','GQCda','ypssi','TVDvy','QMNsS','feGDB','Dual\x20inhibitor\x20of\x20VEGFR\x20and\x20HER\x202\x20tyrosine\x20kinase','video[data-src]','rpBsw','bookmarkBtn','Trametinib','jgvwC','toString','Dual\x20inhibitor\x20of\x20MET\x20and\x20HER\x202\x20tyrosine\x20kinase','none','incorrect','XKguZ','Panabinostat','target','dEOKv','CuUvO','loeAh','helGG','VeyfG','ljTbI','Bosutinib','qvBle','test','zZfUY','Neratinib','now','dMURC','HLMjI','QDXkl','rkBuv','Behcet\x20syndrome','xuLHZ','classList','eQwNr','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','pHAbF','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','TzgAG','UeGJU','15138fDADLj','iAUaI','<p><strong>Palbociclib</strong>\x20is\x20a\x20<strong>cyclin-dependent\x20kinase</strong>\x20(CDK)\x204/6\x20inhibitor.&nbsp;It\x20is\x20approved\x20for\x20use\x20in\x20<strong>advanced</strong>\x20or\x20<strong>metastatic\x20ER-positive</strong>&nbsp;<strong>HER2-negative</strong>&nbsp;<strong>breast\x20cancer.</strong>&nbsp;</p>\x0a<p>Ruxolitinib\x20is\x20an\x20inhibitor\x20of\x20Janus\x20associated\x20kinases:\x20JAK1\x20and\x20JAK2.&nbsp;</p>\x0a<p>Tramitenib\x20and\x20cobimetinib\x20are\x20inhibitors\x20of\x20serine-threonine\x20kinases.</p>','cRWfF','Diethylstilbestrol','<p>The\x20clinical\x20scenario\x20is\x20suggestive\x20of\x20<strong>metastatic\x20melanoma</strong>.&nbsp;The\x20recombinant\x20interleukin-2\x20(IL-2)\x20preparation\x20that\x20is\x20approved\x20for\x20use\x20in\x20metastatic\x20melanoma\x20is&nbsp;<strong>aldesleukin.</strong>&nbsp;It\x20acts\x20as\x20an&nbsp;<strong>IL-2\x20agonist</strong>\x20and\x20is\x20also\x20approved\x20for\x20use\x20in\x20metastatic\x20renal\x20cell\x20cancer.</p>\x0a<p><strong>Denileukin\x20diftitox</strong>\x20is\x20an\x20immunotoxin\x20made\x20from\x20the\x20recombinant\x20combination\x20of\x20IL-2\x20and\x20the\x20catalytically\x20active\x20fragment\x20of\x20diphtheria\x20toxin.&nbsp;It\x20is\x20approved\x20for\x20use\x20in\x20<strong>cutaneous\x20T\x20cell\x20lymphoma.</strong></p>\x0a<p>Imatinib\x20and\x20nilotinib\x20are\x20a\x20BCR/ABL\x20tyrosine\x20kinase\x20inhibitor.</p>','Aldesleukin','innerHTML','<p><strong>Apalutamide</strong>&nbsp;is\x20an&nbsp;<strong>androgen\x20receptor\x20inhibitor</strong>\x20indicated\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20non-metastatic\x20castration-resistant<strong>\x20prostate\x20cancer.</strong></p>','YHNnX','RWFDV','ubklG','GZWti','OGyNg','dCsbu','AuhXI','qBank','zNhoC','TQFbX','LDkZJ','choices','LZedF','Constipation','jVIUL','CmqfZ','tQAQK','quizFile','EPYdM','dqUin','question_images','YJuxj','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','Rituximab','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','totalQuestions','quizHierarchy','No\x20solution\x20available.','button','yghOn','A\x2060-year-old\x20woman\x20was\x20diagnosed\x20with\x20melanoma.\x20Sentinel\x20lymph\x20node\x20biopsy\x20showed\x20malignant\x20cells.\x20Which\x20of\x20the\x20following\x20drugs\x20used\x20in\x20this\x20condition\x20is\x20a\x20MEK\x20inhibitor?','bnZoa','mXiBH','lUASh','red','<p><strong>Thalidomide\x20</strong>use\x20is\x20associated\x20with<strong>\x20peripheral\x20neuropathy</strong>\x20and\x20is\x20usually\x20avoided\x20in\x20HIV-associated\x20peripheral\x20neuropathy\x20as\x20it\x20can\x20worsen\x20the\x20condition.</p>\x0a<p>It\x20is\x20being\x20investigated\x20as\x20an\x20<strong>orphan\x20drug</strong>\x20for:</p>\x0a<ul>\x0a<li>Recurrent\x20aphthous\x20ulcers</li>\x0a<li>GVHD</li>\x0a<li>Behcet\x20syndrome</li>\x0a<li>primary\x20brain\x20malignancies</li>\x0a<li>Kaposi\x27s\x20sarcoma</li>\x0a<li>Crohn&rsquo;s\x20disease.</li>\x0a</ul>\x0a<p>It\x20is\x20approved\x20for\x20use\x20in\x20multiple\x20myeloma\x20and\x20erythema\x20nodosum\x20leprosum.</p>','nav-btn-marked-review','performanceModal','ZtkBo','tFfVR','Amplification\x20of\x20wild-type\x20kinase\x20gene','uOmpw','TaAVt','Amifostine','BHsEb','closest','zocbT','fVzfA','block','<div\x20class=\x22mt-4\x22><img\x20src=\x22','2\x20and\x204\x20only','hrTvj','FKhKO','lGPCn','\x20>\x20','hVTpe','PHkyc','bPNCg','questionIndex','JwHrN','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','RqaRD','MXSnx','yCcFw','loadSource','timed_exam','ujtqF','<p><strong>Lenalidomide,</strong>\x20which\x20is\x20a\x20congener\x20of\x20thalidomide,&nbsp;<strong>suppresses\x20bone\x20marrow</strong>\x20and\x20is\x20associated\x20with\x20significant\x20leukopenia.</p>\x0a<p>Lenalidomide\x20use\x20is\x20associated\x20with\x20a&nbsp;<strong>lesser</strong>&nbsp;incidence\x20of\x20<strong>sedation,\x20constipation,</strong>\x20and\x20<strong>neuropathy</strong>\x20when\x20compared\x20to\x20thalidomide.&nbsp;</p>','IOWOT','FNozI','addEventListener','nEmGQ','pesLV','accuracy','question_audio','lnkWG','ukFej','Rucaparib','href','gfMlT','reload','mmzOz','BCXwr','quizPerformanceData','questionReviewSection','DOYsw','Romidepsin','280328Wishnt','explanation_audio_eng','Vorinostat','reduce','crsDC','nav-btn-incorrect','<p><strong>Sorafenib</strong>&nbsp;is\x20indicated\x20as\x20a\x20first-line\x20treatment\x20for\x20<strong>unresectable\x20hepatocellular\x20carcinoma</strong>.\x20It&nbsp;is\x20an\x20<strong>angiogenesis</strong>&nbsp;<strong>inhibitor.</strong>&nbsp;</p>\x0a<p><strong>Hepatocellular\x20carcinoma\x20management:</strong></p>\x0a<ul>\x0a<li>Resection,\x20ablation,\x20and\x20other\x20physical\x20measures\x20are\x20the\x20mainstay.</li>\x0a<li>Only\x20two\x20drugs\x20(angiogenesis\x20inhibitors)\x20are\x20approved\x20in\x20this\x20condition:\x0a<ul>\x0a<li><strong>Sorafenib</strong>\x20(first-line)</li>\x0a<li><strong>Regorafenib</strong>\x20(second-line).</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a<p>Sunitinib\x20and\x20thalidomide\x20are\x20not\x20indicated\x20in\x20hepatocellular\x20carcinoma.</p>','stats','OKXaL','XWMkh','aKIRL','DSgHd','getAttribute','dCzqh','NhOQe','forEach','VuMwt','Neuropathy','correctCount','Option\x20','progressBar','referrer','LMssu','<p\x20style=\x22text-align:\x20justify;\x22>The\x20clinical\x20scenario\x20points\x20towards\x20a\x20diagnosis\x20of\x20metastatic\x20ovarian\x20cancer.<strong>\x20Rucaparib</strong>\x20is\x20a\x20poly\x20ADP-ribose\x20polymerase/\x20<strong>PARP</strong>\x20<strong>inhibitor&nbsp;</strong>approved\x20for\x20the&nbsp;treatment\x20of&nbsp;<strong>advanced\x20ovarian\x20cancer.</strong></p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>PARP\x20is\x20a\x20nuclear\x20protein\x20that\x20transfers\x20ADP-ribose\x20from\x20NAD<sup><span\x20class=\x22s1\x22>+\x20</span></sup>to\x20target\x20proteins\x20and\x20this\x20plays\x20an\x20important&nbsp;role\x20in\x20the\x20DNA\x20damage\x20response.\x20Rucaparib\x20and\x20<strong>olaparib</strong>\x20are\x20PARP\x20inhibitors.</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Option\x20A:\x20Palbociclib&nbsp;is\x20a\x20selective\x20inhibitor\x20of\x20the\x20cyclin-dependent\x20kinases\x20CDK4\x20and\x20CDK6.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20metastatic\x20breast\x20cancer.&nbsp;</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Options\x20C\x20&amp;\x20D:\x20Vorinostat\x20and\x20romidepsin\x20are\x20histone\x20deacetylase\x20inhibitors.</p>','xFZmS','SNWtr','Tisagenlecleucel','incomplete','HcxPL','UGdrS','hDdwU','lXbTE','NRXnt','vpYmr','timeSpent','rcYYv','mBKAg','yIbPT','zZveU','MhqDS','203uxecUu','WKTmj','Gefitinib','<p><strong>Tamoxifen</strong>\x20is\x20a\x20<strong>selective\x20estrogen\x20receptor\x20modulator</strong>\x20that\x20is\x20indicated\x20for\x20<strong>hormone-responsive\x20breast\x20cancer.</strong>&nbsp;</p>\x0a<p>It\x20is\x20approved\x20for\x20endocrine\x20treatment\x20of\x20women\x20with\x20ER+\x20metastatic\x20breast\x20cancer\x20or\x20following\x20primary\x20tumor\x20excision\x20as\x20adjuvant\x20therapy.</p>','MVXvu','bCSMX','questionMedia','data-option-index','mjEPv','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','HCVzN','div','Mxavt','iNOoi','CBfzK','Sedation','lyxyV','<p><strong>Hypertension</strong>\x20is\x20one\x20of\x20the\x20<strong>characteristic\x20side\x20effects</strong>\x20of\x20<strong>angiogenesis\x20inhibitors</strong>\x20like\x20<strong>bevacizumab</strong>.&nbsp;</p>\x0a<p>The\x20mechanism\x20is\x20not\x20clear\x20but\x20may\x20be\x20related\x20to<strong>\x20decreased</strong>\x20endothelial\x20<strong>nitric\x20oxide\x20production</strong>.&nbsp;Patients\x20receiving\x20higher\x20doses\x20and\x20prolonged\x20treatment\x20might\x20require\x20antihypertensive\x20medications.</p>\x0a<p>Bevacizumab\x20can\x20be\x20used\x20in\x20the\x20treatment\x20of\x20metastatic\x20colon\x20cancer,\x20in\x20combination\x20with\x20FOLFOX\x20or\x20FOLFIRI\x20regimen.\x20It\x20can\x20also\x20be\x20used\x20in\x20the\x20treatment\x20of\x20non-small\x20cell\x20lung\x20cancer.</p>','uXeLL','xDRha','HKKYA','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','-600\x20text-white\x22>','Both\x20A\x20and\x20B','A\x204-year-old\x20child\x20who\x20was\x20being\x20evaluated\x20for\x20pancytopenia\x20is\x20diagnosed\x20with\x20acute\x20lymphoblastic\x20leukemia.\x20Which\x20of\x20the\x20following\x20is\x20the\x20first\x20gene\x20therapy-based\x20treatment\x20approved\x20for\x20use\x20in\x20this\x20condition?','ZAVRT','NVYfp','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','ldLxt','ArrowRight','currentQuestion','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','Dinutuximab','nav-btn-answered','HbJsA','WebFT','Overexpression\x20of\x20MDR\x20gene','src','SDxGV','wNTPX','lfPbR','Febuxostat','AYkdV','lVGns','kRdrf','getElementById','log','search','info','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','currentMode','MKdHw','reviewQuestionsContainer','hBnTZ','review-question\x20','wDffF','fsgTw','RsgcZ','GkDQQ','ariLn','<p><strong>Vismodegib</strong>\x20acts\x20as\x20a\x20competitive\x20<strong>antagonist</strong>\x20of\x20the\x20SMO\x20(smoothens\x20hedgehog)\x20receptor\x20in\x20the\x20<strong>hedgehog\x20signaling\x20pathway</strong>.&nbsp;</p>\x0a<p>Hedgehog\x20signaling\x20plays\x20a\x20key\x20role\x20in\x20stem\x20cell\x20regulation\x20and\x20tissue\x20regeneration.\x20Basal\x20cell\x20carcinoma\x20(BCC)\x20is\x20associated\x20with\x20dysregulation\x20of\x20this\x20pathway.\x20Vismodegib\x20is\x20indicated\x20in\x20patients\x20with\x20<strong>metastatic</strong>\x20or<strong>\x20relapsed\x20BCC.&nbsp;</strong></p>\x0a<p>Option\x20A:&nbsp;Vemurafenib\x20is\x20a\x20BRAF\x20kinase\x20inhibitor.&nbsp;</p>\x0a<p>Option\x20C:&nbsp;Olaparib\x20is\x20an\x20inhibitor\x20of\x20PARP\x20[Poly\x20(ADP-ribose)\x20polymerase]\x20enzyme.&nbsp;</p>\x0a<p>Option\x20D:&nbsp;Neratinib\x20is\x20an\x20irreversible\x20inhibitor\x20of\x20HER-2\x20and\x20EGFR.</p>','onclick','Imatinib','<p><strong>Ponatinib</strong>\x20is\x20a\x20<strong>third-generation</strong>\x20BCR-ABL\x20kinase\x20inhibitor.</p>\x0a<p>Classification\x20of&nbsp;<strong>BCR-ABL\x20kinase\x20inhibitors</strong>:&nbsp;</p>\x0a<ul>\x0a<li><strong>First-generation</strong>:\x20most\x20likely\x20to\x20develop\x20resitance.\x0a<ul>\x0a<li>Imatinib&nbsp;</li>\x0a</ul>\x0a</li>\x0a<li><strong>Second-generation</strong>:\x20active\x20against\x20imatinib-resistant\x20CML\x20cases\x20but\x20not\x20against\x20T315I\x20mutant\x20cases.&nbsp;\x0a<ul>\x0a<li>Nilotinib</li>\x0a<li>Dasatinib&nbsp;</li>\x0a<li>Bosutinib&nbsp;</li>\x0a</ul>\x0a</li>\x0a<li><strong>Third-generation</strong>:\x20active\x20against&nbsp;T315I\x20mutant\x20CML\x20cases\x20and\x20other\x20known\x20mutant\x20cases.&nbsp;\x0a<ul>\x0a<li>Ponatinib</li>\x0a</ul>\x0a</li>\x0a</ul>','cQayW','IbvIx','OGeeG','Denileukin\x20diftitox,\x20a\x20drug\x20approved\x20for\x20the\x20treatment\x20of\x20recurrent/refractory\x20cutaneous\x20T-cell\x20lymphomas,\x20is\x20an\x20immunotoxin\x20made\x20of:','lYGHX','LeiWm','Increase\x20in\x20metabolism\x20of\x20P\x20glycoprotein','gjRYN','OcoHR','totalTimeResult','mpDZS','ktUYo','flex','incorrectResult','Prostate\x20cancer','RvBRx','qlxoH','TacwF','Bortezomib','trace','iYFhB','eFzoC','quizSidebar','ctOWm','yEEJI','2IWtWZK','Which\x20of\x20the\x20following\x20is\x20not\x20a\x20histone\x20deacetylase\x20inhibitor?','A\x20patient\x20presented\x20with\x20abdominal\x20pain.\x20Imaging\x20revealed\x20a\x20mass\x20in\x20the\x20small\x20intestine\x20and\x20a\x20lesion\x20in\x20the\x20liver.\x20A\x20diagnosis\x20of\x20a\x20c-KIT\x20positive\x20gastrointestinal\x20stromal\x20tumor\x20with\x20liver\x20metastasis\x20was\x20made\x20on\x20further\x20evaluation.\x20What\x20is\x20the\x20drug\x20of\x20choice?','kcBbL','mHTJZ','ibZnM','abcyx','TzvUo','SLYKX','NRavC','clIGH','wvhNn','fill','markedForReview','https://cdn1.dailyrounds.org/uploads/7470297a361d4f2f98615f96cafa7386.JPEG','toLowerCase','LyQMN','gray','Dayok','submitSection','SrdYl','IizYd','UIVTf','XfcDm','FgMjx','Imatinib\x20is\x20indicated\x20in\x20which\x20of\x20the\x20following\x20patients?','IdHxq','notAttempted','lxEwn','Seborrheic\x20keratoses','onOMB','YVfSL','vKizn','bsvRd','solution','kNPHL','1,\x203\x20and\x205','Bevacizumab','eCzYG','vkqyf','OfPaZ','nVXjm','custom_quiz.html','LYPYO'];_0x50fb=function(){return _0x5496f1;};return _0x50fb();}function retakeQuiz(){const _0x4546db=_0x573d1a,_0x62e564={'qxWUy':_0x4546db(0x43a),'vALUn':function(_0x2e7bf9,_0x4570cc){return _0x2e7bf9(_0x4570cc);},'NqjVh':_0x4546db(0x236),'HBNZY':function(_0x3ddd23,_0x3e3070){return _0x3ddd23===_0x3e3070;},'bPNCg':_0x4546db(0x432),'qvBle':_0x4546db(0x242),'HncLE':'customQuizData','wDffF':function(_0x3b1edf){return _0x3b1edf();}};_0x62e564[_0x4546db(0x489)](confirm,_0x62e564['NqjVh'])&&(window[_0x4546db(0x2d7)][_0x4546db(0x4bb)]['endsWith']('custom_quiz.html')&&(_0x62e564[_0x4546db(0x273)](_0x62e564[_0x4546db(0x35f)],_0x62e564[_0x4546db(0x30b)])?_0xf84a76[_0x4546db(0x316)]['add'](_0x62e564['qxWUy']):localStorage[_0x4546db(0x2bf)](_0x62e564[_0x4546db(0x1fb)])),_0x62e564[_0x4546db(0x3dc)](clearProgress),location[_0x4546db(0x376)]());}function loadBookmarkedQuestions(){const _0x55e3f0=_0x573d1a,_0x30db88={'yWTtE':_0x55e3f0(0x2b0)},_0x16d2bb=JSON['parse'](localStorage[_0x55e3f0(0x1f5)](_0x30db88[_0x55e3f0(0x203)]))||[];_0x16d2bb[_0x55e3f0(0x38c)](_0x4acf62=>{const _0x4122b6=_0x55e3f0;_0x4acf62[_0x4122b6(0x337)]['includes'](quizName[_0x4122b6(0x40d)]()['replace'](/ /g,'-'))&&(_0x4acf62[_0x4122b6(0x360)]<questionsData['length']&&(questionStates[_0x4acf62['questionIndex']][_0x4122b6(0x485)]=!![]));});}function toggleBookmark(){const _0x33372f=_0x573d1a,_0x18c838={'BYFnV':_0x33372f(0x2b0),'eFzoC':function(_0x2ce25b){return _0x2ce25b();},'EyTwq':function(_0x11a009){return _0x11a009();}},_0x152f7e=!questionStates[currentQuestionIndex]['bookmarked'];questionStates[currentQuestionIndex][_0x33372f(0x485)]=_0x152f7e;let _0xf1da69=JSON[_0x33372f(0x470)](localStorage[_0x33372f(0x1f5)](_0x18c838['BYFnV']))||[];if(_0x152f7e){const _0x2e2321={'quizName':quizName,'quizFile':window[_0x33372f(0x2d7)][_0x33372f(0x4bb)][_0x33372f(0x4a2)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x33372f(0x30f)]()};_0xf1da69[_0x33372f(0x1d3)](_0x2e2321);}else _0xf1da69=_0xf1da69[_0x33372f(0x450)](_0x458350=>!(_0x458350['quizFile']['includes'](quizName[_0x33372f(0x40d)]()[_0x33372f(0x269)](/ /g,'-'))&&_0x458350[_0x33372f(0x360)]===currentQuestionIndex));localStorage[_0x33372f(0x478)](_0x33372f(0x2b0),JSON[_0x33372f(0x43e)](_0xf1da69)),_0x18c838[_0x33372f(0x3fa)](updateBookmarkButton),_0x18c838[_0x33372f(0x26f)](updateQuestionNav);}function updateBookmarkButton(){const _0x199ea5=_0x573d1a,_0x476f7d={'PPKWP':'bookmarkBtn','FXeXF':_0x199ea5(0x3ba),'oSmJa':_0x199ea5(0x281)},_0x47d45a=document['getElementById'](_0x476f7d['PPKWP']),_0x95ab52=document[_0x199ea5(0x3d2)](_0x199ea5(0x493)),_0x3ef8eb=questionStates[currentQuestionIndex][_0x199ea5(0x485)];_0x47d45a[_0x199ea5(0x225)]=_0x3ef8eb?_0x476f7d[_0x199ea5(0x231)]:_0x476f7d['oSmJa'],_0x95ab52[_0x199ea5(0x235)]=_0x3ef8eb?_0x199ea5(0x292):_0x199ea5(0x4a6);}function toggleMarkForReview(){const _0x30d9ba=_0x573d1a,_0x39ae76={'TzvUo':function(_0x1b6966){return _0x1b6966();}};questionStates[currentQuestionIndex][_0x30d9ba(0x40b)]=!questionStates[currentQuestionIndex][_0x30d9ba(0x40b)],updateMarkReviewButton(),_0x39ae76[_0x30d9ba(0x405)](updateQuestionNav);}function updateMarkReviewButton(){const _0x1294f9=_0x573d1a,_0x12c848={'uNwUW':_0x1294f9(0x31a),'LvJIr':'Marked'},_0x488713=document[_0x1294f9(0x3d2)](_0x1294f9(0x2f0)),_0x507ae6=document['getElementById']('markReviewText'),_0x1b5107=questionStates[currentQuestionIndex][_0x1294f9(0x40b)];_0x488713[_0x1294f9(0x225)]=_0x1b5107?_0x12c848[_0x1294f9(0x47d)]:_0x1294f9(0x430),_0x507ae6['textContent']=_0x1b5107?_0x12c848[_0x1294f9(0x22b)]:_0x1294f9(0x2c0);}function previousQuestion(){const _0xab2dc4=_0x573d1a,_0x140bf7={'ariLn':function(_0x26f758,_0x31321d){return _0x26f758-_0x31321d;},'NhOQe':function(_0x256a31){return _0x256a31();},'LZedF':function(_0x175c6a,_0x3ba58a){return _0x175c6a>_0x3ba58a;},'bVZNF':function(_0x48d1a8,_0x436d38){return _0x48d1a8!==_0x436d38;}};_0x140bf7[_0xab2dc4(0x332)](currentQuestionIndex,0x0)&&(questionStartTime&&(_0x140bf7[_0xab2dc4(0x251)](_0xab2dc4(0x232),_0xab2dc4(0x1fe))?questionStates[currentQuestionIndex][_0xab2dc4(0x39f)]+=_0x140bf7[_0xab2dc4(0x3e0)](Date['now'](),questionStartTime):(_0x53bbc4&&(_0x33d4bf[_0x55c052]['timeSpent']+=_0x140bf7[_0xab2dc4(0x3e0)](_0x2bdad7[_0xab2dc4(0x30f)](),_0x46cd9a)),_0x49a2de=_0x19fcf0,_0xd63492(),_0x140bf7[_0xab2dc4(0x38b)](_0xf70231))),currentQuestionIndex--,displayQuestion(),_0x140bf7['NhOQe'](saveProgress));}function nextQuestion(){const _0x4ad123=_0x573d1a,_0x47b881={'NbgGP':_0x4ad123(0x452),'xuLHZ':function(_0x4242d3,_0x4c7e65){return _0x4242d3/_0x4c7e65;},'wNTPX':function(_0x1149f7,_0x177793){return _0x1149f7%_0x177793;},'ivaHO':function(_0x3eed07,_0x5df28b){return _0x3eed07+_0x5df28b;},'BowBg':function(_0x479579,_0x49bae9){return _0x479579-_0x49bae9;},'IKoTq':function(_0x460a67,_0x1d5d9a){return _0x460a67<_0x1d5d9a;},'SqYAn':function(_0x309a26,_0x7f13){return _0x309a26-_0x7f13;},'LxPQv':function(_0x35d40b,_0x198392){return _0x35d40b!==_0x198392;},'aUhDE':_0x4ad123(0x26a),'kuQCR':function(_0x3b5f01){return _0x3b5f01();},'cjoTv':'test','cidPE':function(_0x377e5e,_0x1044e1){return _0x377e5e===_0x1044e1;},'IdHxq':_0x4ad123(0x367),'zgDde':function(_0x4e214a,_0x13d914){return _0x4e214a===_0x13d914;},'feGDB':_0x4ad123(0x469),'boGxb':_0x4ad123(0x1f3),'rxqdm':_0x4ad123(0x3d6),'ASzTk':_0x4ad123(0x415),'wVmZI':function(_0x4e9b9c){return _0x4e9b9c();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x4ad123(0x39f)]+=_0x47b881[_0x4ad123(0x1dd)](Date['now'](),questionStartTime));if(_0x47b881['IKoTq'](currentQuestionIndex,_0x47b881[_0x4ad123(0x48f)](questionsData[_0x4ad123(0x248)],0x1)))_0x47b881[_0x4ad123(0x259)](_0x47b881['aUhDE'],_0x4ad123(0x329))?(currentQuestionIndex++,_0x47b881[_0x4ad123(0x4aa)](displayQuestion),_0x47b881[_0x4ad123(0x4aa)](saveProgress)):(_0x2f016c++,_0x5a7936['status']=_0x47b881['NbgGP']);else{if(currentMode===_0x47b881['cjoTv']||_0x47b881[_0x4ad123(0x2c6)](currentMode,_0x47b881[_0x4ad123(0x418)])){if(_0x47b881['zgDde'](_0x47b881[_0x4ad123(0x2f6)],_0x47b881['feGDB']))confirm(_0x47b881[_0x4ad123(0x2e3)])&&submitQuiz();else{_0x5ab24f[_0x4ad123(0x42e)]++,_0x2553c7['notAttempted']--;if(_0x2374f7)_0x496cb1[_0x4ad123(0x283)]++;else _0x41713b[_0x4ad123(0x258)]++;}}else{if(confirm(_0x47b881[_0x4ad123(0x2e2)])){if(_0x47b881['LxPQv'](_0x47b881[_0x4ad123(0x1d8)],_0x47b881['ASzTk'])){const _0x549a30=_0x4d6276[_0x4ad123(0x445)](_0x47b881[_0x4ad123(0x315)](_0x26925d,0x3c)),_0x3ffb60=_0x47b881[_0x4ad123(0x3cc)](_0x2e7b81,0x3c);_0x3862da[_0x4ad123(0x3d2)](_0x4ad123(0x47e))[_0x4ad123(0x235)]=_0x47b881['ivaHO'](_0x47b881[_0x4ad123(0x263)](_0x549a30,':'),_0x3ffb60[_0x4ad123(0x2fd)]()[_0x4ad123(0x2bb)](0x2,'0'));}else currentQuestionIndex=0x0,_0x47b881[_0x4ad123(0x243)](displayQuestion),_0x47b881[_0x4ad123(0x4aa)](saveProgress);}}}}function startTimer(){const _0x2d9253=_0x573d1a,_0x44115f={'lUASh':_0x2d9253(0x447),'rTXfM':_0x2d9253(0x398),'QDXkl':'TlVAM','mrHJk':function(_0x4290ea){return _0x4290ea();},'tQAQK':function(_0x56cf67,_0xaa4f96){return _0x56cf67===_0xaa4f96;},'ikcSk':_0x2d9253(0x367),'KHaVL':function(_0x574fba,_0x3a4005){return _0x574fba(_0x3a4005);},'ioKTE':function(_0x5c07fa){return _0x5c07fa();},'tKClz':function(_0xce6bfd,_0xe8be31,_0x152f0d){return _0xce6bfd(_0xe8be31,_0x152f0d);}};if(timer)_0x44115f['KHaVL'](clearInterval,timer);timeRemaining=0x78,_0x44115f[_0x2d9253(0x473)](updateTimerDisplay),timer=_0x44115f['tKClz'](setInterval,()=>{const _0x31bae8=_0x2d9253,_0x51f2c7={'YVfSL':_0x44115f[_0x31bae8(0x347)],'EJDeo':_0x44115f[_0x31bae8(0x2ad)]};if(_0x31bae8(0x4a0)!==_0x44115f[_0x31bae8(0x312)])timeRemaining--,_0x44115f[_0x31bae8(0x276)](updateTimerDisplay),timeRemaining<=0x0&&(clearInterval(timer),_0x44115f[_0x31bae8(0x336)](currentMode,_0x44115f[_0x31bae8(0x21a)])?submitQuiz():_0x44115f['mrHJk'](nextQuestion));else{if(_0x4d4ee7)return;const _0x3d7a45=_0x4d096e[_0x31bae8(0x470)](_0x4b7191[_0x31bae8(0x1f5)](_0x51f2c7[_0x31bae8(0x41d)]))||{};_0x3d7a45[_0x29ee81]={'questionStates':_0x5a8f44,'stats':_0x2f9d6c,'currentQuestionIndex':_0x9f7edc,'currentMode':_0x1f18ed,'status':_0x51f2c7['EJDeo'],'lastSeen':new _0x11521c()[_0x31bae8(0x249)]()},_0x29b9c8[_0x31bae8(0x478)]('userHistory',_0x37a01b[_0x31bae8(0x43e)](_0x3d7a45));}},0x3e8);}function updateTimerDisplay(){const _0x52547a=_0x573d1a,_0x18cb08={'cjbdI':'timeDisplay','mmzOz':function(_0x399de4,_0x5ac750){return _0x399de4+_0x5ac750;}},_0x445136=Math[_0x52547a(0x445)](timeRemaining/0x3c),_0x1a64ef=timeRemaining%0x3c;document[_0x52547a(0x3d2)](_0x18cb08['cjbdI'])[_0x52547a(0x235)]=_0x18cb08[_0x52547a(0x377)](_0x445136,':')+_0x1a64ef[_0x52547a(0x2fd)]()[_0x52547a(0x2bb)](0x2,'0');}function toggleSidebar(){const _0xe21fc1=_0x573d1a,_0x4e1115={'heTqL':_0xe21fc1(0x3fb)};document[_0xe21fc1(0x3d2)](_0x4e1115[_0xe21fc1(0x1e0)])['classList'][_0xe21fc1(0x2dd)](_0xe21fc1(0x4ad));}document[_0x573d1a(0x36c)]('DOMContentLoaded',()=>{const _0x37186e=_0x573d1a,_0x484b51={'zvhzk':_0x37186e(0x471),'rkBuv':function(_0x5aa1d8){return _0x5aa1d8();},'lxEwn':_0x37186e(0x3a2),'CuUvO':_0x37186e(0x2e0),'RsgcZ':_0x37186e(0x228),'TDIhR':'none','bdDpi':_0x37186e(0x428),'cSOjN':'VVnBo','KAZSX':_0x37186e(0x354),'hqTqx':_0x37186e(0x3f1),'ZtDWr':function(_0xdd0f56){return _0xdd0f56();}};if(resume){if(_0x484b51[_0x37186e(0x313)](loadProgress)){if(_0x484b51[_0x37186e(0x41a)]===_0x484b51[_0x37186e(0x305)]){if(_0xa44475){const _0x253a6f=_0x5a8e61['apply'](_0x2a20e8,arguments);return _0x1c4bae=null,_0x253a6f;}}else document[_0x37186e(0x3d2)](_0x484b51['RsgcZ'])[_0x37186e(0x46c)][_0x37186e(0x2b4)]=_0x484b51[_0x37186e(0x42a)],_0x484b51[_0x37186e(0x313)](initializeQuiz);}else _0x484b51[_0x37186e(0x313)](clearProgress),document['getElementById'](_0x484b51[_0x37186e(0x3de)])[_0x37186e(0x46c)][_0x37186e(0x2b4)]=_0x37186e(0x3f1);}else{if(!window['location'][_0x37186e(0x4bb)][_0x37186e(0x2a1)](_0x484b51['bdDpi'])){if(_0x484b51[_0x37186e(0x436)]!==_0x484b51[_0x37186e(0x2b3)])clearProgress(),document[_0x37186e(0x3d2)]('modeModal')['style']['display']=_0x484b51['hqTqx'];else{_0x3efc3a[_0x37186e(0x3d2)](_0x37186e(0x431))[_0x37186e(0x324)]=_0x484b51[_0x37186e(0x264)];return;}}else _0x484b51[_0x37186e(0x44a)](initializeQuiz);}}),document['addEventListener'](_0x573d1a(0x21b),function(_0x5d3d31){const _0x3ce837=_0x573d1a,_0x4f0886={'XdIph':function(_0x2088e1,_0x3dcf22){return _0x2088e1-_0x3dcf22;},'oZHbf':function(_0x349fbd,_0x2836b9){return _0x349fbd(_0x2836b9);},'gfMlT':_0x3ce837(0x221),'PoJNR':function(_0x32af16,_0x1a3630){return _0x32af16(_0x1a3630);},'BCXwr':function(_0x40288b,_0x6919aa){return _0x40288b!==_0x6919aa;},'deVnd':_0x3ce837(0x228),'IOWOT':_0x3ce837(0x34b),'lGPCn':_0x3ce837(0x43a),'tAzcj':function(_0x52c74f,_0x1eacd4){return _0x52c74f>=_0x1eacd4;},'rsZbP':function(_0x2bdf65,_0x5b8040){return _0x2bdf65<=_0x5b8040;},'tZeGb':function(_0x2fa6c9,_0xb07ff0){return _0x2fa6c9-_0xb07ff0;},'wVCQK':function(_0x3efa0b,_0xd21731){return _0x3efa0b(_0xd21731);},'EOGKp':function(_0x431f53,_0x46ef20){return _0x431f53<_0x46ef20;},'QPkND':function(_0x8ebbb3,_0x278e38){return _0x8ebbb3===_0x278e38;},'dEOKv':'ArrowLeft','aiCyw':_0x3ce837(0x3c1),'mAKvx':'HzUCh','LYPYO':function(_0x1b4322){return _0x1b4322();},'VsCMc':_0x3ce837(0x3c2),'HKKYA':function(_0x5ea411,_0x27c3b1){return _0x5ea411===_0x27c3b1;},'yaUen':_0x3ce837(0x4a3),'GquqE':_0x3ce837(0x288),'YjPZj':function(_0x3e26fc,_0x466f3f){return _0x3e26fc===_0x466f3f;},'Mxavt':_0x3ce837(0x30c),'vMDcW':function(_0x3aa123,_0x2c1a17){return _0x3aa123===_0x2c1a17;},'GQCda':_0x3ce837(0x367),'RDLcE':function(_0x30f691){return _0x30f691();},'NZUJz':function(_0x482d1c,_0x58b32c){return _0x482d1c===_0x58b32c;},'LzrsK':function(_0x15f599,_0x4ff15d){return _0x15f599===_0x4ff15d;},'zQzwQ':function(_0x3958f3){return _0x3958f3();}};if(_0x4f0886[_0x3ce837(0x378)](document[_0x3ce837(0x3d2)](_0x4f0886[_0x3ce837(0x4cd)])[_0x3ce837(0x46c)][_0x3ce837(0x2b4)],_0x3ce837(0x2ff)))return;if(document[_0x3ce837(0x3d2)](_0x4f0886[_0x3ce837(0x36a)])[_0x3ce837(0x316)][_0x3ce837(0x223)](_0x4f0886[_0x3ce837(0x35b)])===![])return;if(_0x4f0886['tAzcj'](_0x5d3d31[_0x3ce837(0x220)],'1')&&_0x4f0886[_0x3ce837(0x47c)](_0x5d3d31['key'],'4')){const _0x54d948=_0x4f0886[_0x3ce837(0x2b5)](_0x4f0886['wVCQK'](parseInt,_0x5d3d31[_0x3ce837(0x220)]),0x1),_0x298c53=document['querySelectorAll'](_0x4f0886[_0x3ce837(0x375)]);if(_0x4f0886['EOGKp'](_0x54d948,_0x298c53[_0x3ce837(0x248)]))selectOption(_0x54d948);}else{if(_0x4f0886[_0x3ce837(0x25f)](_0x5d3d31[_0x3ce837(0x220)],_0x4f0886[_0x3ce837(0x304)])){if(_0x4f0886[_0x3ce837(0x25f)](_0x4f0886[_0x3ce837(0x23e)],_0x4f0886[_0x3ce837(0x1ed)])){const _0x11a49e=_0x4f0886[_0x3ce837(0x4bf)](_0x4f0886[_0x3ce837(0x1e9)](_0x41e330,_0x49eb31['key']),0x1),_0x22339a=_0x4890fa['querySelectorAll'](_0x4f0886[_0x3ce837(0x375)]);if(_0x11a49e<_0x22339a['length'])_0x4f0886[_0x3ce837(0x4ba)](_0x36eb0d,_0x11a49e);}else _0x4f0886[_0x3ce837(0x429)](previousQuestion);}else{if(_0x4f0886[_0x3ce837(0x25f)](_0x5d3d31['key'],_0x4f0886[_0x3ce837(0x2d1)])||_0x4f0886[_0x3ce837(0x25f)](_0x5d3d31[_0x3ce837(0x220)],'\x20'))_0x5d3d31['preventDefault'](),_0x4f0886[_0x3ce837(0x429)](nextQuestion);else{if(_0x5d3d31[_0x3ce837(0x220)][_0x3ce837(0x40d)]()==='b'&&(_0x4f0886[_0x3ce837(0x3b9)](currentMode,_0x3ce837(0x219))||_0x4f0886[_0x3ce837(0x3b9)](currentMode,_0x4f0886['yaUen'])))_0x4f0886['BCXwr']('qWpKg',_0x4f0886[_0x3ce837(0x2c2)])?toggleBookmark():_0x5d360d[_0x5c9481][_0x3ce837(0x39f)]+=_0x4f0886[_0x3ce837(0x4bf)](_0x44c548[_0x3ce837(0x30f)](),_0x5c024b);else{if(_0x4f0886[_0x3ce837(0x25f)](_0x5d3d31[_0x3ce837(0x220)][_0x3ce837(0x40d)](),'m')&&(_0x4f0886['YjPZj'](currentMode,_0x4f0886[_0x3ce837(0x3b1)])||_0x4f0886[_0x3ce837(0x2a9)](currentMode,_0x4f0886[_0x3ce837(0x2f2)])))_0x4f0886['RDLcE'](toggleMarkForReview);else _0x4f0886[_0x3ce837(0x498)](_0x5d3d31[_0x3ce837(0x220)]['toLowerCase'](),'s')&&(_0x4f0886[_0x3ce837(0x27f)](currentMode,_0x3ce837(0x30c))||_0x4f0886[_0x3ce837(0x25f)](currentMode,_0x4f0886['GQCda']))&&_0x4f0886[_0x3ce837(0x43d)](submitQuiz);}}}}});</script>

</body></html>